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Despite the World Health Organisation's recommenda¬
tions made in 1978, there is still a lack of concurrence
on the histopathological classification of the carcinomas
of the nasopharynx (NPC). A major reason for this is that
the exact histogenesis of the tumours is not understood.
This study, therefore, was commenced in order to try and
define the histochemical properties of the epithelia in
the normal and in the abnormal nasopharynx, including
those showing both intraepithelial and malignant changes.
The aim was to do as much of the work as possible or
paraffin processed nasopharyngeal tissues, in order that
a retrospective study could be undertaken, and so that
the results, if significant, could be applied to routine
diagnostic work.
Conventional histochemical techniques confirmed ear¬
lier studies on the type and distribution of mucins, and
the distribution of reticulin fibres and stainable
keratin in the nasopharynx.
A new monoclonal antibody, MA6, which was hoped to
be specific or selective for nasopharyngeal carcinoma,
did not specifically locate nasopharyngeal epithelial or
carcinoma cells by immunohistochemistry. The antigen with
which MA6 reacts is widely distributed among both normal
and abnormal tissues.
Work was also started on the identification of the
Epstein-Barr virus nuclear antigen (EBNA) by modifying
the well known anti-complement immunofluorescence test
for use on paraffin sections. Many attempts were un¬
successful. The antigen may have been disrupted by the
tissue preparation process, or the primary antiserum may
have lacked the high titre and avidity required for im-
munohistochemistry on paraffin sections.
Using immunohistochemistry of cytokeratins, a pat¬
tern of reactivity emerged. Pseudostratified columnar
epithelium stained more intensely with AE1AE3 monoclonal
antibody than intermediate epithelium, which in turn
stained more intensely than the stratified squamous
epithelium. Biopsies showing intraepithelial changes
showed a decrease in staining intensity when compared
with adjacent normal epithelial counterparts. In par¬
ticular, patches of squamous metaplasia were easily iden¬
tifiable among neighbouring normal epithelium. Twenty-
seven out of 28 carcinomas tested stained with AE1AE3.
There were no identifiable differences in the staining
patterns of the various types of tumour.
Anti-cytokeratin 18 stained only the upper parts of
the columnar epithelial cells. Intermediate and
stratified squamous epithelia were consistently negative.
Areas of hyperplastic columnar epithelium were positive,
but all other intraepithelial lesions were unstained.
None of the carcinomas stained.
AE1AE3 could be useful for identification of car¬
cinomas if a differential diagnosis were required between
lymphoma, which would be negative, and carcinoma. AE1AE3
also identified squamous metaplasia, whose significance
in the nasopharynx is not yet understood. Squamous
metaplasia could be a lesion which is a precursor to
malignancy, as it has proved to be in other sites.
Anti-cytokeratin 18 was consistent in that it only
identified the simple pseudostratified columnar
epithelium. If nasopharyngeal carcinomas carry the same
cytokeratin subsets as their precursor cells, then the
lack of reactivity with the carcinomas would indicate
that the precursor was not columnar epithelium. However,
it is not known whether the expression of cytokeratins
changes during the malignant transformation in the
nasopharynx. This result, therefore, does not answer the
question of histogenesis.
The results of this study indicate that there is
selectivity in the histochemical reactions of the normal,
the abnormal and the cancerous epithelium of the
nasopharynx. Further work will be required to identify
the precise differences of these histochemical changes,
with a view to aiding histopathological diagnosis and of
understanding the histogenetic origin of this common
malignant tumour.
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The southern Chinese, including those living in Hong
Kong are among a number of populations who have a high
risk for nasopharyngeal carcinoma (NPC).
Possibly because high incidences of NPC are limited
to restricted areas, some aspects of NPC research have
been neglected. There have been many studies of the im¬
munology, virology and epidemiology of NPC but the study
of the histology of these tumours so far has been
limited. This is because there is no universally accepted
histological classification and related to this, the his¬
togenesis of the tumours has not been established.
NPC arises from the nasopharyngeal epithelium, but
exactly which type of epithelium is not known. The tumour
cells have a variety of morphologies and it is because of
this heterogeneity there has been a long and confusing
debate about their classification. As yet there is no ac¬
cepted explanation for this variety of appearances. At an
international symposium on nasopharyngeal carcinoma held
in Japan in 19771 five different classifications were
promulgated, no two of which were completely interchange¬
able. Since 1977 new classifications have continued to be
submitted to the literature.
A consequence of these problems of histogenesis and
classification is that it has been impossible to corre¬
late the results of the many studies that have been made,
which discuss histopathology together with other factors
such as epidemiology, treatment and prognosis. Some
recent studies have indicated that the histological type
of tumour may correlate with the patients' outcome. It is
therefore essential that a widely accepted histological
classification is established.
This histochemical study was embarked upon with
these problems of histogenesis and classification ir
mind. It was an attempt to find an objective way of
defining the different epithelial cell types in normal
and abnormal nasopharynx. Following on from this it was
hoped that the nature of early intraepithelial changes
could be established. Logically this could lead to ways
of distinguishing the different types of NPC. Ultimately
it may be possible to establish whether there are dif¬
ferences in the histogenesis of the different types of
NPC.
The aim was to carry out as much of the work as pos'
sible on sections of formalin fixed and paraffin wax em¬
bedded tissue, as this is the standard method of tissu
preparation for histological study. Tissues thus prepare(
are routinely stored in histology laboratory files
Retrospective studies can easily be made by cutting ne
sections off the stored tissue blocks.
Tissues studied included a lymphoblastoid cell line,
Raj i (whose cells contain one of the Epstein Barr virus
antigens, Epstein Barr virus nuclear antigen- EBNA), a
NPC tumour xenograft, some post mortem specimens of
nasopharynx and a number of nasopharyngeal biopsies show¬
ing a range of lesions, from mild intraepithelial
changes through to NPC. With the exception of some
preparations of Raji cells and some pieces of the
xenograft, these tissues were formalin fixed, paraffin
processed, and sectioned at 2 or 3 microns.
A number of histochemical investigations were per¬
formed on the preparations in order to establish a his¬
tochemical profile of the tissues. These included some
well established techniques to identify mucins, reticulin
and keratin, and some immunohistochemical techniques
using several different antisera.
2. LITERATURE REVIEW
2.1. ANATOMY OF THE NASOPHARYNX
Embryologically the nasopharynx is derived from a
recess in the primitive pharynx in the cranial part of
the foregut. The recess is formed when the embryo is only
a few weeks old.2
In the adult the pharynx extends from the base of
the skull to the oesophagus and larynx. It is divided
into three parts: nasal, oral and laryngeal pharynx. The
nasopharynx lies behind the nasal cavities and is the
widest part of the pharynx. Because of its bony framework
A R
it is always patent under normal conditions.'''
Anteriorly it is continuous with the nasal cavities
through the posterior nares which are separated by the
posterior edge of the nasal septum. The anterior wall in¬
cludes the postero-superior surface of the soft palate
which forms the incomplete floor of the nasopharynx. The
roof of the nasopharynx is formed by the thick layers of
the mucous membrane and periosteum on the under surface
of the basilar part of the occipital bone. The roof is in
continuation with the posterior wall. The posterior wall
is formed by the mucous membrane that overlies the
prevertebral muscles and fascia, which in turn overlie
the anterior arch of the atlas vertebra.
Unlike the other two parts of the pharynx, the
nasopharynx has only a respiratory function. During swal¬
lowing it is closed off from the oral pharynx by the
elevation of the soft palate. At other times there is
free communication with the oral pharynx.6
The lateral walls of the nasopharynx contain the
openings of the auditory or Eustachian tubes whose upper
and posterior lips are prominent and cartilaginous and
are called tubal elevations or Eustachian cushions.
On either side, folds of the mucous membrane, the
salpingopharyngeal folds, descend from the lower edge of
each tubal opening to fade out gradually on the pharyn¬
geal wall. Another less distinct pair of ridges of the
mucous membrane pass down from the front edge of the
tubal openings towards the soft palate, the salpingopala-
tal folds. Behind the openings of the tubes are deep ver¬
tical clefts, the pharyngeal recesses or fossae of
s
Rosenmuller.
The lamina propria of this part of the nasopharynx
contains lymphoid tissue, which forms part of Waldeyer's
ring of pharyngeal lymphoid tissue. Part of Waldeyer's
ring, the nasopharyngeal tonsil or adenoids, is situated
in the area where the roof and posterior wall of the
nasopharynx merge into one another close to the openings
of the Eustachian tubes.3'5'6
Lymphatics drain into glands in the retropharyngeal
and parapharyngeal recesses which in turn drain into the
upper deep cervical chain of the neck. There is free
2
cross over of lymphatics.
2.2. HISTOLOGY OF THE NASOPHARYNX
The nasopharynx is lined by various types of
epithelia which are derived from the ectoderm. The
epithelium is supported by a connective tissue layer
called the lamina propria which contains mixed glands,
lymphoid tissue of Waldeyer's ring, and some collections
of lymphocytes without the formation of follicles. Col¬
lectively the epithelium and the lamina propria are known
as the nasopharyngeal mucosa. A further connective tissue
layer called the submucosa connects the mucosa to the un¬
derlying structures. The epithelium is separated from the
lamina propria by a basal lamina composed of reticulin,
collagen and mucopolysaccharide.7
Because of its relative inaccessibility, knowledge
of the accurate dimensions and of the histology of the
normal nasopharyngeal mucosa is incomplete.8 The only ex¬
tensive histological study seems to have been made by Ali
m 1965. He calculated that the area of the epithelial
lining of the adult nasopharynx is approximately 50 sg.
cms. Ali identified three types of epithelium: stratified
squamous, pseudostratified ciliated columnar and inter¬
mediate (or transitional) epithelium.
All three epithelial cell types are found during
foetal development. Ciliated cells begin to appear when
the foetus measures 29mm crown-rump, and they rapidly
develop into the pseudostratified columnar epithelium
which is the dominant type at birth. Patches of squamous
epithelium begin to appear in 84mm foetuses. The ciliated
epithelium begins to be replaced by small patches of
squamous epithelium in 84mm foetuses. At full term the
roof of the nasopharynx shows mostly pseudostratified
columnar ciliated epithelium with patches of non-ciliated
columnar, intermediate and squamous epithelium.
In the adult nasopharynx almost 60% of the anterior
wall and 80%- 90% of the posterior wall are covered with
stratified squamous epithelium. The lateral walls show a
pattern of alternating patches of ciliated and squamous
epithelia which are separated by islets of intermediate
epithelium.
At least 13 of the anterior wall abutting the pos¬
terior nares and a narrow strip of the roof are lined by
pseudostratified ciliated columnar epithelium. Ap¬
proximately 40% of the anterior wall and 15-20% of the
posterior wall are covered with ciliated epithelium. Al¬
most 12 the area of the lateral walls is lined by
ciliated epithelium distributed in irregular patches al¬
ternating with islets of squamous and intermediate
epithelia.9
The intermediate epithelium forms a wavy junctional
zone separating the nasopharynx from the oropharynx.12
There are numerous islets of intermediate epithelium
covering the salpingopharyngeal fold, the pharyngeal
recess in the lateral walls and the lining of the pharyn¬
geal tonsils in the posterior wall.
Intermediate epithelium is stratified and 5 or 6
layers thick.11'13'14 The deepest layers of cells are
cuboidal followed by a layer of polyhedral cells and on
the surface is a layer of rounded cells. Intercellular
bridges are not found by electron microscopy (EM).
The deep layers of stratified squamous epithelium
are cuboidal and only the more superficial mature layers
are flattened.7 The cells are non keratinised, although
keratohyalin granules can sometimes be seen as basophilic
cytoplasmic granules.9'10 The keratohyalins are antece-
dents of the keratins of the epidermis.3
The pseudostratified ciliated columnar epithelium is
composed of several cell types, all of which are in con¬
tact with the basal lamina, but not all reach the sur¬
face. The cells are ciliated and many of them are mucin
producing goblet cells.
2.3. EPIDEMIOLOGY OF NASOPHARYNGEAL CARCINOMA
Most of the neoplasms of the nasopharynx are
malignant; only about 10% are benign. Among the malig¬
nancies it is the epithelial tumours, that is the
nasopharyngeal carcinomas, that are the most common in
all races and regions of the world.8
2.3.1. GEOGRAPHY
Nasopharyngeal carcinoma occurs commonly in southern
Chinese populations, including those living in Hong Kong
and in other countries of SE Asia who live a traditional
Chinese way of life. Southern Chinese born in Western
environments such as Australia, Hawaii and California
retain an intermediate risk. NPC accounts for less than
1% of cancers among European races: the corresponding
figure among the Chinese in Guangzhou is over 50% and
in Hong Kong, 18%.2 In Guangdong province de The reported
that NPC comprised 43% of all cancers in males and 16% in
females.18
In Hong Kong it ranks after bronchus and liver as
the third most common malignancy.19 The male-female ratio
is 2.49- l.17 It is the most common cancer among Hong
Kong Chinese between the ages of 15 and 34.
In both Hong Kong and Guangdong the incidence rates
of NPC for both sexes among the fishing community who
live on boats are about two-fold higher than those for
the rest of the population.17'18'29
An intermediate incidence for NPC has been reported
around the Mediterranean in Tunisia,21 Algeria22 and
Morocco.23 There is also an intermediate risk in the Rift
Valley in Kenya and Uganda and in the Sudan.
Blot et al reported a high incidence among Alaskan
natives who are of Eskimo, Indian and Aleutian origin.
These people are racially Mongoloid and are widely con¬
sidered to be of Asian origin.2 Greenlanders, racially
an Eskimo-Caucasian mixture also have an increased
risk.23
NPC is more common in men than women in all areas.
This male preponderance is highest among the Chinese with
reported rates of between 2.6 and 4.4 to 1, while in
Europe the ratio is less than 2 to l.16
Besides ethnic and geographical features, several
other factors have been suggested to be contributory to
the development of NPC.
2.3.2. FAMILIAL INCIDENCE AND GENETIC ASSOCIATION
After studying several families of Chinese NPC
patients, Ho25 reported that there is a higher frequency
of NPC among close blood relatives of NPC patients than
in patients suffering from other types of cancer. 5-6% of
the NPC cases seen at the Guangzhou cancer hospital occur
in families where two or more cases have been diag¬
nosed.18 Chan et al reported an increased risk of
developing NPC associated with HLA antigens B17, A2 and
BW46.26 There is also a much higher risk if HLA A2 and
BW46 occur together. The authors suggested that the
posession of such genetic factors can influence the sus¬
ceptibility of the patient to environmental influences
such as exposure to EBV and carcinogens.
2.3.3. EPSTEIN BARR VIRUS
Epstein Barr Virus (EBV) belongs to the gamma herpes
group of DNA viruses.2 It is a ubiguitous virus, being
present in most human populations.28 EBV was first dis¬
covered by Epstein in 1964 when studying electron
micrographs of cultured lymphoblastoid cells from an
African Burkitt's lymphoma (BL) tumour biopsy.29'30 Fur¬
ther experiments using indirect immunofluorescence on
these cell lines and sera from BL patients confirmed that
this was a new virus.31'32 EBV is also associated with
infectious mononucleosis.33
Burkitt's lymphoma is a form of undifferentiated
lymphoma which commonly occurs in Africa and New Guinea,
while being rare in other countries.34'35 It frequently
presents as an osteolytic lesion of the jaw in children 6
- 10 years old.' It is the most common childhood
tumour in Africa. The incidence in endemic areas of
Equatorial Africa and New Guinea can be as high as
10100,000 children The tumour nearly always contains
the EBV genome39 and certain EBV antigens.40 EBV produc-
ing cell lines can be derived from the tumours.'
Patients with African Burkitt's lymphoma have elevated
antibody titres to EBV antigens.41 Most Burkitt's lym-
phomas in America and Europe do not contain EBV DNA,
indicating that the tumour may have several causative
factors.
Infectious mononucleosis is a self limiting EBV in¬
fection which tends to affect adolescents and younc
adults living in regions with relatively higt
socioeconomic conditions, and only affects individuals
who lack antibodies to EBV.43'44 It produces fever, ton¬
sillitis, lymphadenopathy and hepatosplenomegaly. Uncom-
plicated cases run their course in one to four weeks.
Because of the early age of infection with EBV in most
parts of the world, very few young adults are susceptible
to infectious mononucleosis and it is virtually unknown
m most areas.
EBV was first associated with NPC by Old et al47 wh
found that serum from NPC patients formed precipitate
with extracts from BL cell lines. Later studies confirme(
the association46 and extended it to the demonstration o:
EBV antibodies in NPC patients' sera by immunofluores¬
cence tests using EBV containing lymphoblastoid eel!
lines as the source of antigen 49,59
The role of EBV in the pathogenesis of NPC is not
understood, but the association of the two is very strong
in cases of NPC from throughout the world.51 Whether the
virus is a passenger or is aetiologically responsible for
the development of the tumour is still not conclusively
settled. Herpes virus particles have not been
definitely observed in EM studies of biopsy
material.' However there is a large volume of in¬
direct evidence to associate EBV with NPC. Both EBV
DNA39,55,56,57,58 an EBV nuclear antigen (EBNA)59,50 are
present in the malignant epithelial cells, while biopsies
from other head and neck carcinomas do not contain EBV
DNA39,57nor do they contain EBNA.50
In developing and tropical countries, including
those areas with high risk for NPC, most children have
been infected by EBV by the age of ten years.51 NPC
patients produce characteristic patterns of serum an¬
tibodies to EBV antigens. EBV has an intricate life cycle
and different antigens are produced during the various
phases of the cycle.61 In NPC patients, serum antibodies,
particularly IgA,62,63 can be demonstrated in relation to
three antigen systems found in the infected cells.'
Viral capsid antigen (VCA) is a structural component of
the virus. The early antigens (EA), when investigated in
super infected lymphoblastoid cell lines seem to be com¬
posed of at least six distinct polypeptides which are
thought to play a role in the transformation of the cell
to an immortalised state.66
The Epstein Barr virus nuclear antigens (EBNA) are
products synthesised during the guiescent phase. They are
localised on the chromosomes and are also thought to pla
a role in the immortalisation of cells.67 EBNA is no
known to be composed of two distinct polypeptides desig¬
nated EBNA I and EBNA II.68 The classical EBNA equates
with EBNA I which is a protein mol wt 60-70Kd with an
IEP at pH 4.6. EBNA II is more tightly bound to the
chromosome and is a basic protein (hence the tight
binding), mol wt 60-70Kd with an IEP at pH 9.2.67,69,70
NPC has been classified histologically by the WHO
into three categories based on the degree of differentia-
tion of the tumour cells. The undifferentiated car¬
cinomas, WHO types II and III, have been associated with
EBV for many years. These patients have elevated
serological IgA responses to VCA and one of the early an¬
tigens (EA-d)64,72 and DNA hybridisation experiments show
the malignant cells also contain EBV DNA.74 This is
regardless of ethnic or geographical origin, as high risk
Chinese,73 medium risk Africans and low risk Caucasian
patients74 with undifferentiated NPC all contain EBV DNA
in their tumour cells.
EBV serology of WHO type I (that is tumours showing
evidence of squamous differentiation) patients is similar
to that of control populations and these tumours have
been thought not to have any special association with EBV
infection.72,75. However recent DNA hybridisation work
has indicated that the WHO I tumours do contain EBV DNA,
though in much lower genome equivalents than the types II
and III generally contain.
The serological response to VCA, EA and EBNA in-
creases with the severity or stage (stage according to
Ho) of the disease. The presence of high IgA titres
against VCA has been used as the basis of a series of
serological surveys undertaken in Wuzhou city, China
since 1980, involving at least 20,726 people aged 40
years and over. As citizens reach 40 years they are also
recruited to the survey. Those with raised serum IgA
titres against VCA were followed up. Altogether 35 cases
of NPC were identified, many in the early asymptomatic
stages.7 6'77
EBV was thought until recently to be strictly a lym-
photropic virus with a very narrow host cell range which
would infect only B lymphocytes in vitro, transforming
and immortalising them. Monoclonal antibody studies
have shown that B lymphocyte cell membranes carry a
complement receptor, the C3d receptor of which the CR2
molecule functions as a receptor for EBV. Using the
same two monoclonal antibodies against the C3dEBV recep¬
tor of B cells, Young et al80 demonstrated, by im¬
munofluorescence studies on frozen sections, that the C3d
receptor also appears on oral and nasopharyngeal squamous
epithelia.
Evidence of EBV replication in exfoliated oropharyn¬
geal cells of infectious mononucleosis patients was
reported in 197781 but this was not confirmed until
recently with further in situ hybridisation experiments
on throat washings from infectious mononucleosis
patients.
Suggested sites in normal tissues for a lifelong
reservoir of EBV, investigated by in situ hybridisation,
are parotid gland,83 and respiratory tract.84 Additional
in situ hybridisation work on various tumours has shown
that EBV genomes are present in thymic carcinoma and
salivary gland carcinoma86 indicating that EBV could also
be an aetiological factor in these tumours.
2.3.4. HERBAL MEDICINES
Medicines containing croton oil, derived from the
seeds of the shrub Croton tiglium, are used as throat and
nasal balms or oils by Chinese.87 Hirayama and Ito88
identified a significantly higher relative risk of NPC
among patients who had frequently used such herbal
medicines.
In a study of 495 Chinese medicinal herbs, 16 herbs
including croton oil were able to activate EBV in cul-
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tures of latently infected lymphoblastoid cells.
2.3.5. INHALANTS
In a study of Malaysian Chinese, occupational ex¬
posure to inhalants such as smoke and dust were sig¬
nificantly associated with NPC.90 A similar association
was found with both smoking and working in poor ventila¬
tion.87 However an additional study which compared risk
factors among Hong Kong Chinese and Los Angeles Chinese
did not support inhaled carcinogens as major risk fac¬
tors .91
2.3.6. SALTED FISH
Ho reported that one of the traditional foods fed to
Southern Chinese children in the weaning and post weaning
periods is salted fish added to congee. In a survey of
NPC patients, Ho found that salted fish was commonly
eaten by boat people from an early age. Boat people are
reported to have a particularly high incidence of
NPC.7'8'0 Recent epidemiological studies have shown a
significant association between salted fish intake, par¬
ticularly during early childhood and NPC.90'91'92'93
Salted fish has been found to contain dimethyl-
nitrosamine.94 In a study in which WA albino rats were
fed steamed salted fish, 420 rats developed tumours in
the nasal and paranasal cavities, but not any of the con-
trols.95
2.4. HISTOGENESIS OF NASOPHARYNGEAL CARCINOMA
The histogenesis of the various types of NPC is not
understood. The tumours show histological features of
epithelial tumours and undoubtedly arise from the
epithelium of the nasopharynx.96 There are three types of
epithelium: stratified sguamous, intermediate and pseudo-
stratified ciliated columnar.9 Whether the tumours arise
from one or all of these epithelial types is unknown.
Several authors agree that the tumours arise from the
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squamous or pseudostratified columnar epithelium.''
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In a series of 31 autopsy cases of NPC, Teoh considered
that all the tumours arose from the stratified squamous
epithelium of the nasopharynx.
Q Q
In an EM study of 20 specimens Prasad concluded
that all types of NPC arise from squamous cells which
were either there to start with or after having undergone
squamous differentiation. This was on the basis of find¬
ing tonofi1aments converging onto desmosomes in the
malignant cells.
Batsakis et al10 suggested that different types of
tumour arise from normal epithelia that are at different
stages of differentiation. The undifferentiated tumours
arise from undifferentiated stem cells and the well dif-
ferentiated squamous cell and adenocarcinomas arise from
more highly differentiated or determinate epithelial
cells. They suggested that intermediate epithelium is
particularly susceptible to oncogenic stimuli.
2.5. INTRAEPITHELIAL LESIONS OF THE NASOPHARYNX
Most fully mature, or differentiated cells retain a
restricted range of variability, and are able to undergo
some changes of phenotype in response to environmental
stimuli.100
Several distinct non malignant lesions which may be
attributed to environmental stimuli, can be identified in
the nasopharyngeal epithelium. These may or may not
progress to malignancies.
2.5.1. METAPLASIA
This is the conversion in post natal life of one
differentiated cell type to another. True metaplasias
arise in epithelial renewal tissues when there is chronic
tissue regeneration caused by trauma, infection or abnor¬
mal hormonal stimulation. The presence of metaplasias in
a situation of continuous cellular renewal indicates that
the transformation occurs at the level of the stem cells
as these are the only cells that survive the tissue in¬
definitely. The existence of small foci of metaplasia
suggests a monoclonal origin of the lesions. For a
monoclonal lesion to grow to macroscopic size the trans¬
formed tissue must compete with regenerating normal
tissue. Changes from glandular to squamous epithelium are
thought to give greater resistance to mechanical and
TOT
chemical irritation.
This squamous metaplasia is apparently reversible on
the removal of the irritating stimulus. However there are
instances where the cancers probably arise from a cell
within a patch of metaplasia and more closely resemble
the metaplasia than the normal parent tissue. The fairly
uncommon squamous cell carcinomas and adenocarcinomas of
the bladder probably arise within areas of metaplasia.
Squamous cell carcinoma of the bronchus is also believed
to arise from patches of squamous metaplasia. Here
squamous metaplasia is attributed to smoking, although
smoking probably has other carcinogenic effects which may
contribute to the development of squamous cell car-
101
cmoma.
The occurrence of metaplasia in areas of chronic
tissue regeneration is well established. Implications in
terms of cancer risk may be small in some tissues but are
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probably considerable in others. Areas of squamous
metaplasia are identifiable in the nasopharyngeal
epithelium. The implications of these metaplasias are
unknown.
2.5.2. HYPERPLASIA
An increase in the number of cells in an adult
tissue is termed hyperplasia. Hyperplasia may be divided
into two different but overlapping types: (a) physiologi¬
cal and (b) pathological or neoplastic. Physiological hy¬
perplasia is a normal reaction of tissue to environmental
stimuli such as irritation and infection, while neoplas¬
tic hyperplasias are caused in part at least by an in¬
herited abnormality within the cells. Physiological hy¬
perplasia occurs because of an increase in the proportion
of replicating cells which continue to divide instead of
undergoing differentiation and eventual death. On removal
of the stimulus, physiological hyperplasia is revers-
ible.100 Areas of hyperplasia are seen in all types of
nasopharyngeal epithelium.
2.5.3. KOILOCYTES
Cells of the epithelium that are undergoing
koilocytic change are characterised by a prominent
nucleolus, a perinuclear halo and vacuolated cytoplasm.
They can occur in all epithelial layers and have been
reported in 'hairy' leucoplakia lesions of the tongue and
gingiva of human immunodeficiency virus (HIV) infected
patients, in plantar and common warts of the skin and in
condylomatous lesions of the cervix uteri. Several inves¬
tigations using DNA hybridisation and immunohis-
tochemistry have associated these lesions with both
EBV102'103 and human papillomavirus (HPV)104'105'106 in¬
fections. Cells of similar appearance are seen in
nasopharyngeal epithelium, although they have not been
associated with viral infection.
Condylomatous lesions of the cervix have a high rate
of spontaneous regression and it has been suggested that
many lesions classified as cervical intraepithelial
neoplasia grade I (see below) are in fact HPV induced
condylomata.104
2.5.4. INTRAEPITHELIAL NEOPLASIA
This expression was first introduced with regard to
the precursor lesions of sguamous cell carcinoma of the
cervix, as cervical intraepithelial neoplasia (CIN). The
implication of the term was that regardless of mor¬
phological appearance, all precancerous intraepithelial
abnormalities of the cervix belong to the same family of
lesions. The lesions are graded from I to III, with CIN
grade I corresponding to the morphologically lesser le-
sions and grade III to the classical severe dysplasia or
carcinoma in situ. All the lesions have common nuclear
abnormalities such as nuclear enlargement, hyperchromasia
and an increased number of mitoses, many occurring in ab¬
normal locations and possibly showing abnormal mitotic
figures. The lesions differ from one another by the
degree of epithelial disarrangement and cell maturation.
In CIN grade I lesions the epithelial stratification
is well preserved and the cells have abundant well dif¬
ferentiated cytoplasm. CIN grade III shows a marked dis¬
arrangement of the epithelial structure and scanty or
keratinised cytoplasm. The CIN grade II lesions show
nuclear and cytoplasmic features intermediate between the
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two groups.
It has been suggested that a comparable sequence of
events takes place in the nasopharynx, and that the
genesis of cancer in the nasopharynx is preceded by
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recognisable intraepithelial lesions.
Nasopharyngeal intraepithelial neoplasia (NPIN) type
I shows isolated atypical cells in the lower two-thirds
of the epithelium or numerous undifferentiated cells in
the lower third. NPIN type II has many undifferentiated
cells in the lower two thirds, while NPIN grade III shows
numerous undifferentiated cells in the full thickness of
the epithelium.108
2.6. HISTOLOGICAL CLASSIFICATION
NPC is the most common type of malignancy of the
nasopharynx, particularly in countries with a high in¬
cidence of the disease. In Singapore, for example, 98.7%
of the malignancies of the NP are carcinomas, whereas in
the UK 70.2% and in Japan 79.2% of nasopharyngeal malig¬
nancies are carcinomas. Adenocarcinomas, lymphomas and
other cancers make up the remainder. 109
NPC can arise from any part of the nasopharynx. The
most common sites are the lateral walls, particularly the
fossa of Rosenmiiller and eustachian cushion, followed by
the roof. Less common sites are the posterior and and an¬
terior walls.2'10'13 The lateral walls are areas where
the intermediate epithelium is most common.10
For some time there has been debate over the his¬
tological subclassification of NPC. This is partly be¬
cause the histogenesis of the tumours has not been
clarified, partly because of its occurrence in a variety
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of histological forms,' partly due to subjective in¬
terpretations by pathologists and partly because some
early u1trastruetura1 studies claimed evidence of
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squamous differentiation in all NPCs. Only those cells
whose cytoplasmic filaments converge into desmosomes are
now considered to have undergone squamous differentia-
tion.10
Malignant tumours of the NP were first described by
Trotter in 1911 as 'endotheliomas'. In 1921 Schminke and
Regaud independently described tumours of the NF
which had an admixture of lymphocytes as
'lymphoepitheliomas.,98 Since then many reports and
classifications have appeared which use these or dif¬
ferent names leading to confusion, particularly because
the term 'lymphoepithelioma' could misleadingly indicate
that the tumours are of mixed lymphoid and epithelial
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origin.
Teoh98 in a study of 31 autopsies considered the
lymphocytes of the so—called lymphoepitheliomas to be in—
cidental components and not an integral part of the
tumours. Yeh13 found that 87% of a series of 1000 malig¬
nancies of the nasopharynx were epidermoid carcinomas. He
identified seven different types based on the degree of
differentiation and the cell morphology. Although he used
it in his classification, Yeh doubted the existence of
lymphoepithelioma as a separate entity. He suggested that
it was a transitional cell carcinoma infiltrating the pre
existing lymphoid tissue of the NP. In this study he
failed to eguate tumour type with prognosis.
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Liang et al classified their series of 50
autopsies and 500 biopsies into three groups and six
types according to the degree of differentiation and the
morphology of the cells. The well differentiated group
include cylindrical cell (adenocarcinoma) and sguamous
cell carcinoma grades I and II. The poorly differentiated
tumours are large cell, fusiform cell and sguamous cell
carcinoma grade III. Liang et al's poorly differentiated
tumour is their pleomorphic cell carcinoma. The authors
equated these groups with modes of spread. The undif¬
ferentiated tumours tending to show both cranial base in¬
vasion and distant metastases while the highly differen¬
tiated tumours tended not to invade the base of the skull
nor to metastasise.
Classifications continued to be submitted to the
literature and during an international symposium on
nasopharyngeal carcinoma held in Kyoto, Japan in 1977,
five different classifications were presented, no two of
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which were completely interchangeable.'''
Descriptive terms used included undifferentiated car¬
cinoma, undifferentiated carcinoma of nasopharyngeal
type, nonkeratinising carcinoma and anaplastic carcinoma.
The diversity of terms used in these and other
classifications, and the absence of a uniform histologi¬
cal classification has not allowed correlation of the
different studies that have appeared in the literature
which discuss histopathology together with other aspects
of NPC such as epidemiology, treatment and prog¬
nosis.10'52'109 in an attempt to rectify the confusion,
in 1978 the WHO proposed a classification into three
types: keratinising squamous cell, non keratinising car¬
cinoma and undifferentiated carcinoma.71 See Table 1.
Since the introduction of the WHO classification,
modifications to the scheme and new classifications have
continued to be submitted to the literature,111'115'110
each claiming to be indicative of prognosis. Table 2 com¬
pares these recent classifications with the WHO class¬
ification.
All of the schemes retain the category of squamous
cell carcinoma (SCO) as a distinct entity. The French
scheme combines the non-keratinising and the keratinising
tumours of WHO together in a single group called undif¬
ferentiated carcinoma of nasopharyngeal type (UCNT). They
justified this division into two categories on the basis
of EBV serology; patients with SCO had low titres of EBV
related antibodies while patients with UCNT had elevated
titres. They also claimed good correlations of age, eth¬
nic origin and survival rates after treatment (no details
supplied), and suggested that SCC and UCNT are two dis-
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tinct diseases of the nasopharynx.
The Taiwan scheme introduces three groups, besides
SCC, based on cell morphology: spindle cell (SC), mixed
cell (MIX) and round cell (RC). Each of these is further
subdivided according to the degree of differentiation.
Types A are undifferentiated and types B are well dif
ferentiated.110





Squamous cell carcinoma (or keratinising
squamous cell carcinoma (SCC). Showing definite
evidence of squamous differentiation with the
presence of intercellular bridges and
keratinisation over most of its extent. It may
be graded as well, moderately or poorly dif¬
ferentiated.
Non-keratinising carcinoma (NK). Showing
evidence of differentiation with a maturation
sequence that results in cells in which
squamous differentiation is not evident on
light microscopy. The tumour cells have fairly
well defined cell margins and show an arrange¬
ment that is stratified or pavemented. A
plexiform pattern is common. There is no
evidence of mucin production, or of glandular
differentiation.
Undifferentiated carcinoma (UC). The tumour
cells have oval or round vesicular nuclei and
prominent nucleoli. The cell margins are indis¬
tinct and the tumour exhibits a syncitial
rather than a pavemented appearance. Spindle
shaped tumour cells are arranged in irregular
and moderately well defined masses andor
strands of loosely connected cells in a lym¬
phoid stroma. These cells do not produce mucin.
TABLE 2. HISTOLOGICAL CLASSIFICATION OF NASOPHARYNGEAL CARCINOMA

























Type B well differentiated















Type B well differentiated
Type Illb with
lymphoid infiltration
The authors claim that this classification corre¬
lates closely with patient outcome. KS has the worst
prognosis with 5 year survival rate of 21.1%, SC 5 year
survival rate of 41% with RC and MIX at 51.2% and 54.1%
respectively. Among the types A and B, the undifferen¬
tiated tumours (A) have a much less favourable outcome
than the well differentiated (B) types.
The Cologne scheme115 essentially follows the WHO
system, but it subdivides the types II and III into Ila
and Ilia (without lymphoid infiltration) and lib and Illb
(with lymphoid infiltration). Patients with SCC have the
worst prognosis, followed by NK and UC. Those with a
heavy lymphoid infiltrate have a significantly better
outcome than those without.
Patients with tumours classified by the WHO scheme
had five year survival rates of 11% for SCC, 27.6% for NK
and 30.1% for UC. Those with a heavy lymphocyte in¬
filtrate, perhaps reflecting a more effective host
response, had a better prognosis over three years but not
over five years. The three and five year survival rates
were better for females (55.3% and 42.3%) than for males
(26.0% and 19.5%) respectively.109
2.7. HISTOCHEMISTRY
Few histochemical studies of the nasopharynx have
been undertaken, and histochemistry has been of little
use as an aid to the diagnosis of NPC.
In Ali's9 comprehensive study of the histology of
the NP he reported that keratohyalin was demonstrated (no
method given) occasionally in intermediate epithelium and
more frequently in the squamous epithelium, particularly
in individuals over 50 years of age. He also identified
melanin pigment using, Schmorls reaction, in the basal
cells of the epithelium. Melanin was more common in In¬
dians and Malays than in Chinese. Numerous mast cells
were demonstrated in the lamina propria using Dominici's
(metachromatic?) stain.
In the nasopharyngeal mucosa, mucin secretion is
confined largely to goblet cells in the ciliated columnar
epithelium with occasional intermediate cells also con¬
taining cytoplasmic mucin. In a thorough histochemical
investigation using twelve techniques including PAS, al-
cian blue, mucicarmine and toluidine blue, Tock Tan118
established that practically all the mucins of the
nasopharynx are either sialidase resistant sialomucins or
sulphated mucins. The submucosal glands also secrete
sialidase resistant sialomucins and sulphated mucins. A
few glands produce neutral mucins only. The gland ducts
produce mucins that are similar to those of the surface
epithelium. Non keratinising and undifferentiated (and
presumably squamous cell) carcinomas do not produce
71
mucins.
Glycogen, demonstrated by Best's carmine, was
reported to be present in the clear cells of an undif¬
ferentiated tumour, and in liver metastases of a second
autopsy case of NPC.8 Liang et al noted that well dif¬
ferentiated tumours were often encapsulated by ar-
gyrophilic reticulin fibres while the poorly differen¬
tiated and undifferentiated tumours were usually without
encapsulation.
Lennert et al119 recommended using Giemsa stain to
help diagnose undifferentiated carcinoma of nasopharyn¬
geal type (UCNT). The grey-blue tumour cells can be
easily distinguished from dark blue lymphocytes and
plasma cells.
UCNT cells are moderately positive for acid phos¬
phatase and weakly positive for non specific esterase
and chloroacetate esterase. Use of these enzyme methods
facilitates the distinction between UCNT, particularly
its metastases, and Hodgkins disease and lymphosarcoma,
which are negative for all three enzymes. 117' 119' 12 0
In a light and electron microscope study of a series
of 434 NPC biopsies Prathap et al121 reported the
presence of intra- and extracellular amyloid in 12% of
the specimens. They demonstrated it for light microscopy
with congo red, crystal violet and thioflavine T and con¬
firmed it with EM studies. The tumours were classified
by the WHO system and amyloid was present in all three
histological types. It was most common in non keratinis-
ing carcinomas with 22% of those examined showing
amyloid.
2.8. IMMUNOHISTOCHEMISTRY
Considerably more use has been made of immunohis-
tochemistry in the diagnosis of NPC, than of his¬
tochemistry.
Epstein Barr virus nuclear antigen (EBNA) was
demonstrated in touch smears made from fresh NPC
biopsies59,60'117 by the anti complement immunofluores¬
cence (ACIF) test.122 The ACIF has been modified to an
anti complement immunoenzyme (ACIE) method using
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peroxidase instead of a fluorescent dye as a label.
These technigues use polyvalent human antisera to EBNA as
the primary antibody.
Various other antigens have been investigated by im-
munohistochemistry as potential markers for NPC, using
both polyclonal and monoclonal antibodies. These include
the epithelial cell markers epithelial membrane antigen
(EMA), carcinoembryonic antigen (CEA) and keratin (or
cytokeratin).124,125,126,127,128,129,130,131,132
EMA is a large glycoprotein which is present on most
secretory epithelia and secreted by many car¬
cinomas.133'134 It was originally demonstrated with an-
tisera raised against defatted human cream.135 It is
widely distributed in human carcinomas,134'135'137 and
occasionally found in lymphomas and plasmacytomas.138
Reports vary as to the value of EMA as a tumour marker.
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Sloane et al found it to be a more efficient tumour
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marker than cytokeratin. Both Pinkus et al and Thomas
and Battifora135 found both monoclonal and polyclonal an¬
tibodies to cytokeratin to be more effective than an¬
tibodies to EMA for the characterisation of epithelial
derived neoplasms.
CEA is an epithelial membrane antigen which was
first identified in human foetal intestine and adult
colon cancer by Gold and Freedman in 1965148'141 and
thought by them to be a specific marker for colorectal
cancer. Immunohistochemical studies have shown that CEA
is a product of normal as well as malignant colonic
cells.142'143'144 It has also been localised in tumours
of the small bowel, testis, breast, thyroid, lung and
cervix.133'145'146'147,148 It ls typically absent from
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sarcomas and lymphomas.
Gusterson et al127 found that their polyclonal an¬
tibodies to EMA and CEA were less reliable for the recog¬
nition of NPC than their polyclonal antibody to keratin.
EMA was weakly positive while CEA was positive in only
two out of 38 carcinomas tested by Bosq et al.130'132 Al]
the carcinomas were negative for the lymphoid markei
leucocyte common antigen and for the melanoma associatec
antigen.130'132
S-100 protein is an acidic, calcium binding protein
initially identified in the brain and called S-100 be¬
cause of its solubility in 100% ammonium sulphate.150 It
was at first used as a marker for glial cells of the
central nervous system and Schwann cells of the
peripheral nervous system,151 but was later found to be
more widely distributed. Melanocytes, chondrocytes,
myoepithelial cells and breast ducts were among the cells
found to express S-100. Their malignant counterparts also
stain with anti S-100, and this led Kahn et al to suggest
that the presence of S-100 in some tumours can be used to
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confirm their histogenesis.
S-100 protein is also present in a number of cells
with dendritic features which have been identified as
both Langerhans cells (or T-zone histiocytes) and inter-
digitating reticulum cells by immunohistochemistry and
ultrastructural studies. These cells have been identified
in a number of pathological specimens, including
Npc.152'153'154 They are thought to have an immunological
role, possibly in the presentation of antigen to T-
lymphocytes.154 Because of their reactivity with an¬
tibodies to S-100 protein it has been suggested that in-
terdigitating reticulum cells are related to cells of the
macrophagemonocyte system.155 In Bosq et al1s study
using a panel of monoclonal antibodies against a number
of tumours, anti S-100 protein gave weak staining in
about half the undifferentiated NPCs tested. The type of
cells stained was not described.130
Wick et al evaluated reactivity of a number of
tumours, including 36 NPCs, with antibodies to placental-
like alkaline phosphatase (PLAP), EMA and cytokeratin.
The NPCs were uniformly negative with PLAP and positive
with EMA and cytokeratin in contrast to the 37 germ cell
tumours which were positive with PLAP and variable with
EMA and cytokeratin antibodies.156
From these and other studies, cytokeratin emerges
the most useful marker for the histological diagnosis of
NPC that has been found to date.
2.8.1. CYTOKERATINS
The cytokeratins are one of the five classes of in¬
termediate filaments that make up part of the filamentous
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cytoskeleton of vertebrate cells. Intermediate fila¬
ments are the lOnm components of the cytoskeleton, as
distinguished from the 6nm actin filaments and the 25nm
microtubules.158 They are composed of a family of five
types of proteins which can be distinguished biochemi¬
cally and immunologically.159 The cytokeratins are
characteristic of epithelial cells; vimentin occurs in
mesenchymally derived cells; desmin filaments are typical
of muscle cells; neurofilaments occur in neurons and
glial filaments are found in astrocytes.160'161
The cytokeratin filaments are composed of a complex
family of at least seventeen different polypeptides (See
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table 3). They were catalogued by Moll-1-0 who distin¬
guished them by their isoelectric points which range from
5.1 to 7.8 and by their molecular weights which range
from 40 to 67Kd.
The seventeen members of the cytokeratin family are
divided into two subfamilies, the type A and type B sub¬
families (or types I and II):

































































The type A subfamily comprises acidic polypeptides
of pi 4.5- 5.5, mol wt 40- 57Kd, that is cytokeratins
(CK) 10 to 19 of Moll's catalogue. 159
The type B subfamily comprises basic polypeptides of
pi 5.5- 7.5, mol wt 52- 68Kd, CK 1-8 of Moll's
catalogue (See table 3).
Each cytokeratin lOnm intermediate filament contains
at least one polypeptide member from each subfamily.
Pairs of cytokeratins consisting of one specific member
of the type A subfamily and one specific member of the
type B subfamily seem to be consistently expressed in
different types of epithelial cells.162 Certain pairs are
only found in simple epithelia (45Kd type A or CK 18 and
52Kd type B or CK 8) while others are found in stratified
epithelia (50Kd type A or CK 14 and 58Kd type B or CK
158,162,163
Besides those cytokeratin polypeptides that are con¬
stant to the lOnm intermediate filaments of each cell
type, subsets of two to ten cytokeratins are expressed in
any given epithelium. The detailed composition of each
subset is heterogeneous and can vary depending upon cell
type, degree of differentiation and disease
state.159'162'164'165 It is not yet understood how the
inclusion of different cytokeratin polypeptides in the
assembly of the lOnm filaments alters the resulting
1 r c
properties of these filaments.
It should therefore be possible to identify and
classify epithelial cells by the composition of their
cytokeratin subset. Most epithelial tissues can be class¬
ified as being simple or stratified, but a few do not
fall into these categories. These include the transi¬
tional epithelium of bladder and tracheal pseudo-
stratified ciliated columnar epithelium. It is possible
that the intermediate and the pseudostratified ciliated
columnar epithelium of the nasopharynx fall into a
similar category. Generally cytokeratins expressed by
these unusual epithelia represent a combination of
stratified and simple types.166'162
Epithelial derived malignancies (carcinomas) con¬
tinue to produce cytokeratins,124'167'168 but comparisons
between the carcinomas and their normal cellular counter¬
parts have shown that the pattern of cytokeratins
produced by the abnormal cells is sometimes quite dif-
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ferent. Some tumours, for example adenocarcinoma of
colon, have been found to express cytokeratin patterns
nearly identical with those produced by their specific
cells of origin. Others, such as breast cancer and
adenocarcinoma of lung, have been found to express only a
subset of the cytokeratins produced in the corresponding
normal tissues.165'167
Antibodies to intermediate filament proteins have
been used extensively as diagnostic markers for various
human neoplasms.168'169 These antibodies can distinguish
between carcinomas, lymphomas, melanomas and sarcomas and
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can be helpful in diagnosing undifferentiated tumours.
Antibodies to cytokeratin have been shown to recognise
tumours of epithelial cell origin.138'157'170'171'172'173
The earliest study involving the identification of
cytokeratin in NPC was by Schlegel et al in 1980.124 They
briefly reported that formalin fixed and paraffin
processed NPC tissues gave strongly positive antibody
reactivity with a rabbit anti human keratin antiserum by
a peroxidase-anti-peroxidase technique. This was followed
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by further studies using polyclonal antisera.''
All the NPCs tested in these reports gave positive stain-
ing. More recent studies have used monoclonal antibodies
to cytokeratin128'129'130'131'132'139 in which the large
majority of carcinomas tested stained positively.
2.8.2. OTHER MARKERS
MA6 is a murine IgM monoclonal antibody174 which
reacts with an antigen found on NPC cells. The immunogen
for MA6 was an immunoprecipitate obtained by counterim-
munoelectrophoresis of serum from an NPC patient and an
extract of lysed Raji cells, a Burkitt lymphoma cell
line.
MA6 reacts with an antigen which has been identified
as a 55Kd glycoprotein, or a group thereof,175 which is
referred to as B-lymphocyte carcinoma cross-reacting an¬
tigen (BLCa). BLCa has been demonstrated on B lym-
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phocytes, on carcinoma cells including NPC and on some
nasopharyngeal epithelial cells.176
In immunofluorescence tests, MA6 reacts with a num¬
ber of B lymphocyte cell lines. Immunoperoxidase staining
of several formalin fixed and paraffin processed tumour
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tissues gave positive staining in carcinomas. Im-
munocytochemistry of impression smears of NPC biopsies
resulted in positive staining in tumour cells, some lym-
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phoid cells and some epithelial cells.
Suspensions of exfoliated NPC cells were subjected
to a direct binding assay using 125i labelled MA6.177 Six
out of nine patients tested gave positive binding.
Results of Western blotting experiments on extracts of
NPC biopsies correlated closely with immunocytochemistry
of impression smears taken from the same specimens before
1 n r
extraction.
2.9. TECHNIQUES USED IN IMMUNOHISTOCHEMISTRY
Immunohistochemistry has been defined as the iden¬
tification of a tissue constituent in situ by means of a
specific antigen-antibody reaction tagged by a visible
label.178 This essentially simple principle is dependent
upon the fact that low molecular weight compounds such as
fluorescein, enzymes and biotin can be attached to an an¬
tibody without interfering with its function as an an-
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tibody. The various technigues used have descended
from an immunofluorescence method of Coons180,181 for the
demonstration of antigens in tissue culture cells. In the
early technigues the specific antibody itself was
1 O f)
labelled (direct method), and later the more sensitive
and versatile indirect method was introduced.182 Fluores¬
cein isocyanate was replaced by fluorescein
1 o o
isothiocyanate which is simpler to conjugate to an¬
tibodies and it has remained the fluorescent label of
choice. It yields an intense apple green fluorescence on
irradiation in the near UV (excitation at 490nm, emission
at 52Onm) .178 Fluorescence methods are still used exten¬
sively because of their speed and simplicity.
Disadvantages inherent in the fluorescence methods
are that they reguire a fluorescence microscope, back¬
ground details cannot be seen clearly and the prepara¬
tions are not permanent because the fluorescent labels
cannot withstand dehydration so agueous mounting media
must be used. Several labels have been used as alterna¬
tives to fluorescent dyes. For light microscopy the en¬
zyme labels have been the most successful. Horseradish
peroxidase184 is most commonly used. The enzyme labels
must be developed histochemically to produce coloured in¬
soluble end products at the site of reaction.
2.9.1. ANTICOMPLEMENT IMMUNOFLUORESCENCE TEST
The anticomplement immunofluorescence (ACIF) test122
was developed to identify EBV antigens in human lym-
phoblastoid cell lines carrying the Epstein Barr virus
and applied to cell smears from two Burkitt's lymphoma
biopsies. The test revealed a complement fixing antigen
localised in the nucleus of the cultured cells and in the
nuclei of the Burkitt's lymphoma cells. The Burkitt's
lymphoma cells showed a more coarsely granular fluores¬
cence than the fine granules of the cultured cells. The
antigen was designated EBV-associated nuclear antigen
(EBNA).
Smears of the cell lines were prepared either in the
cytocentrifuge or by spreading a concentrated suspension
of washed cells on microscope slides, air drying and
fixing in cold acetone. Sera obtained from Burkitt's lym¬
phoma and NPC patients were tested for the EBV capsid an¬
tigen and early antigens. Those with raised titres were
used as test sera. Serum with no detectable EBV an¬
tibodies was used as a source of complement.
The smears were incubated with the test serum (which
had first been diluted optimally and incubated at 56°C foi
30 min. to inactivate complement) together with comple¬
ment at 37°C in a humid chamber. After washing, the seconc
step was an incubation with an optimally diluted fluores¬
cein conjugated rabbit anti human complement. Slides were
examined with a fluorescence microscope.
The ACIF test was subseguently applied to touch
smears of NPC biopsies which had been air dried and
rapidly fixed in cold methanol—acetone. Results showed
granular fluorescence in the nuclei of the malignant
cells. The presence of EBNA positive cells correlated
with raised serum titres of antibodies to EBV antigens.60
Zeng et al modified the ACIF test123'185 to an im-
munoenzymatic method. Their preparations were cold
acetone fixed smears of cells from the NP, which had been
collected by negative pressure suction.185'186 The first
step of the procedure was the same as the ACIF. The
second step of the ACIF was replaced by an incubation
with a horseradish peroxidase conjugated rabbit anti
human complement. The peroxidase was visualised with
diaminobenzidine-hydrogen peroxide which produces a brown
deposit at the site of reaction. Results showed brown
nuclear staining which was comparable with the fluores¬
cence of the ACIF test. EBNA was detected in malignant
cells, hyperplastic cells and ciliated columnar
epithelial cells. The test was weakly positive in
squamous epithelial cells. EBV negative sera gave nega¬
tive results. The authors claimed that the ACIE was more
sensitive than the ACIF test and it was easier to see the
morphology of the cells. In addition it obviated the need
for an expensive fluorescence microscope. The ACIF and
ACIE techniques can only be applied to smears and frozen
sections. They have not yet been successfully used on
paraffin processed sections.117
2.9.2. IMMUNOENZYME METHODS
Since the introduction of enzyme labels for im-
munohistochemistry and the widespread application of the
techniques to paraffin processed tissues, there has been
a proliferation of work in the identification of cell
• 135,149,187,188
markers for tumour diagnosis.
Horseradish peroxidase,18 E. coli alkaline
phosphatase180 and Aspergillus niger glucose oxidase
have been used as antibody labels. Endogenous peroxidase
activity in granulocytes and erythrocytes must be in¬
hibited prior to immunostaining with methanol-hydrogen
peroxide191 or periodate oxidation.192 Endogenous
alkaline phosphatase must be blocked with levimasole193
or periodate oxidation. Glucose oxidase occurs ex¬
clusively in plants and reguires no blocking step. Horse¬
radish peroxidase has become the most commonly used en¬
zyme label. Alkaline phosphatase has been used par¬
ticularly in double immunolabelling technigues189 and is
now becoming popular as a single antigen label.
2.9.3. INDIRECT
More sensitive than the direct method,180 the sec¬
tion is first incubated in primary antibody. After wash¬
ing in buffer, the second, labelled antibody is applied
to the section. The second antibody is from another
species, raised to the IgG of the animal donating the
first antibody.182 Visualisation of the label reveals the
site of the primary antigen. The early methods utilised
fluorescent labels. Enzyme labels were introduced
later.194 The increase in sensitivity is because each
primary antibody binds several molecules of the second
antibody.179
2.9.4. UNLABELLED ANTIBODY-ENZYME METHOD
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The peroxidase-anti-peroxidase (PAP) technigue
involves the use of a stable complex of three peroxidase
molecules and two anti peroxidase antibody molecules
which acts as a third layer antigen. The first layer is
(for example) a rabbit anti antigen, the second layer a
goat anti rabbit IgG and the third layer a rabbit PAP
complex. The PAP is more sensitive again than the in¬
direct method because of the increased amount of label.
The primary antibody can be highly diluted, thus reducing
the amount of background staining, a problem particularly
of polyclonal antibodies. A similar complex using the
alkaline phosphatase-anti-alkaline phosphatase complex
(APAAP) is also in use, particularly for double immunoen-
zymatic labelling189
2.9.5. AVIDIN-BIOTIN
Avidin is an egg white glycoprotein (approx. 68 Kd)
that has a high affinity for the small molecule vitamin H
or biotin (244Daltons). Avidin is a tetramer and has four
binding sites for biotin. By covalently coupling biotin
to an enzyme molecule the enzyme acquires the ability to
bind avidin. Covalent coupling of biotin to antibody
gives the antibody the ability to bind avidin.196 These
properties have been utilised in the avidin-biotin-
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peroxidase methods.' The first step is the primary
antibody; the second a biotinylated antibody raised in
another species against the IgG of the animal donating
the primary antibody; the third step is an avidin-biotin-
peroxidase complex in which three out of the four avail¬
able binding sites on the avidin molecule are occupied by
biotin-peroxidase, the fourth site is free to bind with
the biotin of the second layer antibody. The technique is
considerably more sensitive than the PAP method enabling
high dilutions of primary antibody to be used. It
facilitates the demonstration of antigens which have been
partially lost during fixation and processing. The in¬
creased sensitivity may be due to multiple binding which
brings more enzyme to the site,19 or because the ABC
complex is comparatively small so that penetration of
reagents to the tissue is easier than the with the large
PAP complex.199'200
2.9.6. STREPTAVIDIN-BIOTIN
Despite the high affinity of avidin for biotin,
problems of non specific binding have been reported and
attributed to the stickiness of the carbohydrate moiety
of avidin. In addition the pi of avidin is 10 which may
cause ionic binding with anionic tissues, resulting in
non specific binding.
Streptavidin, which is isolated from cultures of
Streptomyces avidinii, has similar properties to avidin:
it is a tetramer, molecular weight around 60kD and it
binds biotin with an extremely high affinity. On the
other hand it is non glycosylated and has a neutral pi.
These two properties make streptavidin superior to avidin
as a reagent for the detection of biotinylated
on i
molecules. It is now used extensively in immunohis-
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tochemistry for both light and electron microscopy.
2.9.7. ENZYME SUBSTRATES
Probably the most commonly used substrate for
peroxidase development is diaminobenzidine tetrahydroch-
loride with hydrogen peroxide (DAB-H2O2)•200 DAB gives a
brown insoluble deposit at the site of reaction which is
insoluble in alcohol and xylene. Solvent based mounting
media can be used to make permanent preparations with
good resolution. Several alternative substrates are
available but they tend to be less satisfactory than DAB.
The coloured deposits of 3-amino-9-ethyl carbazole
(red)204 and 4-chloro-l-naphthol (blue)205 are alcohol
and xylene soluble so agueous mounting media must be
used. Preparations therefore are not permanent and
resolution is not as good as with synthetic mounting
media. Hanker-Yates reagent (purple)206 deteriorates on
storage and tends to be capricious in use. However these
alternative substrates are useful in double immunoen-
zymatic methods when contrasting coloured deposits are
required.
A substrate for alkaline phosphatase labelled
reagents is naphthol-AS-MX phosphate plus fast red or
fast blue which give red or blue deposits at the reaction
site. The deposits are alcohol soluble so an aqueous
mounting medium is required.207
Glucose oxidase can be visualised with phenazine
methosulphate plus a tetrazolium salt such as p-nitro
blue tetrazolium chloride.150 The end product is resis¬
tant to dehydration and clearing.
2.9.8. PROTEOLYTIC ENZYMES
Preliminary proteolytic enzyme digestion enhances
immunohistochemical staining with a variety of antigens
in paraffin sections, especially if the tissue is for¬
malin fixed, for example immunoglobulins, alpha-l-anti
trypsin and keratin.208'209'210 A number of enzymes have
been evaluated to optimise immunoreactivity of various
tissue antigens, including pronase, papain, pepsin and
trypsin. Several studies have indicated that trypsin is
the most suitable210'211 as digestion is more easily con¬
trolled and morphology is better preserved.
The type of trypsin, the concentration and the di¬
gestion time are important in obtaining good results, and
must be optimised for each laboratory. In an immunohis¬
tochemical study of cytokeratin of a variety of formalin
fixed and paraffin processed carcinomas using both
210
polyclonal and monoclonal antibodies, Pinkus et al ob¬
tained good results with type II porcine trypsin
(Sigma).212
2.9.9. POLYCLONAL AND MONOCLONAL ANTIBODIES
Immunohistochemica1 procedures rely on the
availability of antibodies that will react in a specific
way with the tissue antigen. Until 1975 all antibodies
were produced by injecting a purified preparation of the
antigen into an animal, thus inducing production of
specific antibodies against the antigen. After a suitable
time interval the animal is bled and the serum collected
contains the soluble antibodies. Animals used include
rabbits, goats, swine, sheep, horses and guinea pigs.
However, an immunohistochemical technique is only as
reliable as the specificity of the antibodies used in the
system and the specificity of the primary antibody is
pi O
crucial. These polyclonal antisera are heterogeneous
and contain antibody subpopulations that differ in region
specificity and avidity. They may contain contaminating
antibodies either induced by previous
infectionsimmunisations or evoked by unknown con¬
taminants in the immunogen preparation. Such antisera may
not be suitable for critical immunocytochemistry as the
techniques will indiscriminately detect all antibodies
that bind to a tissue section regardless of
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specificity
The unwanted antibodies are best removed by affinity
purification in which the antigen under investigation is
coupled to a solid support such as cyanogen bromide ac¬
tivated Sepharose beads. The desired antibody population
will bind while the contaminating antibodies are washed
away. The specific antibodies are then eluted. The
problem with affinity purification is that high avidity
antibodies, which are ideal for immunocytochemistry, are
difficult to elute completely. However, affinity
purified antibodies are used extensively in im¬
munocytochemistry.
In 1975 Kohler and Milstein devised an ingenious
method of producing pure and reproducible antibody in un¬
limited quantities.216 Mice of an certain strain, for ex¬
ample, BALBc, are immunised and when the antibody is
being produced the mice are killed. Dissociated plasma
cells from their spleens, the source of the antibodies,
are fused with cultured myeloma cells from the same
strain of mice.
These hybrid cells retain the properties of both
parent cells, that is, of antibody production and of con¬
tinuous growth in culture. The hybrid cell population
will produce as many assorted antibodies as the original
immunised mouse. Pure antibodies are obtained by con¬
tinuously dividing the cultures and testing the super-
natants for antibodies. Only cultures producing the
wanted antibody are kept and these are further divided
and tested until clones derived from a single cell and
producing specific antibody are obtained. The culture
medium contains the antibody to the original antigen,
which is of homogeneous specificity and constant af-
finity.178
A lengthy technique, but as long as the culture is
kept alive, an indefinite supply of monospecific antibody
is available. The advent of monoclonal antibody technol¬
ogy thus circumvents the difficulties of lack of
specificity of polyclonal antibodies. The field of im-
munohistochemistry has benefited enormously from the ap¬
plication of monoclonal antibodies. They react specifi¬
cally with the tissue antigen, giving the minimum of
T 7 8
background staining.
It should be remembered, though, that a monoclonal
antibody against a single well defined antigenic deter
minant does not necessarily mark a single family of
cells. The same (or similar) determinants may be found on
213
cells that are developmentally unrelated.
3. MATERIALS AND METHODS
3. MATERIALS
3.1. CELL LINES
Two cell lines were obtained from Dr DP Huang
Department of Morbid Anatomy, Prince of Wales Hospital,
Shatin, Hong Kong.
3.1.1. RAJI
This is a lymphoblastoid cell line of African
Burkitt's lymphoma origin which has B cell features.217
O 1 O
It carries EBV DNA and the EBV-determined nuclear an-
1 p p
tigen (EBNA) is demonstrable. Raj i cells were used as
a positive control for the modified anticomplement im¬
munofluorescence test (ACIF). The original ACIF test is
used to identify EBNA in cultured cells as well as in
clinical material.59'122
3.1.2. BJA-B
A lymphoblastoid B-cell line from an African
Burkitt-like lymphoma which shows no evidence of the EBV
genome when tested by DNA hybridisation and im¬
munofluorescence for EBNA, EA and VCA.219 BJA-B cells
were used as a negative control in the modified ACIF
test.
These two cell lines were prepared in two ways:
smears and paraffin processed blocks.
3.1.3. SMEARS
A concentrated suspension of pH 7.2 phosphate buf¬
fered saline (PBS) washed cells was spread on clean glass
slides, air dried and fixed in equal volumes of acetone
and methanol at -10 °C, or in 10% buffered formalin or in
periodate-lysine-paraformaldehyde (PLP) for 3 min (see
appendix 1). Smears were stored in a sealed box at -20°C
until used. PLP has been used successfully as a fixative
for immunoe1ectron microscopy and for immunohis-
tochemistry of nervous tissue.220'221
3.1.4. PARAFFIN PROCESSED BLOCKS
PBS washed cells were pelleted by centrifugation and
fixed in equal volumes of -10°C acetone-methanol or in 10
buffered formalin or in periodate-lysine-paraformaldehyde
for 1 hour. The fixed cell pellets were processed to
paraffin wax by a standard 18 hour schedule. They were
sectioned at 2 or 3 microns, mounted on chrome alum-
gelatine coated slides222 (see appendix 1) to ensure
adhesion of the section, and baked in a 56°C oven over¬
night. They were stored at room temperature until used.
3.2. XENOGRAFTS
The undifferentiated form of NPC has proved dif¬
ficult to grow in tissue culture. Consequently tumour
xenografts, grown in athymic nude mice have been used as
a means of studying the tumour under controlled condi¬
tions in a constant and reproducible form.
Two xenografts were obtained from Mrs Margaret Lui,
Institute of Radiation and Oncology, Queen Elizabeth
Hospital, Kowloon, Hong Kong, to test the ACIF method.
One, 1216, contained the EBV genome. The other, 1252, was
negative for EBV. The tumour tissues were halved and
fixed in either -10°C acetone-methanol or 10% buffered
formalin for six hours. The fixed tumour pieces were
processed by a standard 18 hour schedule. They were sec¬
tioned at 2-3 microns, mounted on chrome alum-gelatine
coated slides (see appendix 1) and baked in a 56 °C oven
overnight. They were stored at room temperature in a
closed box until used.
3.3. BIOPSY OF NASOPHARYNGEAL CARCINOMA
A single fresh-frozen biopsy was obtained from Mr
Stephen Lo, Department of Morbid Anatomy, Prince of Wales
Hospital, Shatin (PWH). It was mounted on a cryostat
chuck and sectioned at 5 microns. The sections were
picked up on microscope slides, air dried and fixed in
-10° C acetone-methanol for 10 min. The sections were
wrapped in aluminium foil and stored at -20°C until used.
3.4. AUTOPSY SPECIMENS
Four autopsy specimens of nasopharynx were obtained
from Mr Stephen Cheung, Department of Morbid Anatomy,
PWH. They had been removed by the rapid method o t
Szanto223 and comprised the nasopharynx together witf
part of the sphenoid bone and sphenoid sinus.
3.4.1. A86-76: male, aged 81 years. Cause of death:
carcinoma of oesophageal-gastric junction.
Gross examination: received fixed in buffered for¬
malin, a diamond shaped piece of nasopharyngeal
mucosa approximately 10 10 cm attached at one end
to the sphenoid bone. The openings of the eustachian
tubes,the tubal elevations and the fossa of
Rosenmuller could be seen. The sphenoid bone was
dissected away, and the entire mucosa cut up for
histological examination into 30 blocks (see figure
1) which were processed to paraffin wax by a stand¬
ard 18 hour schedule.
3.4.2. A87-368: male aged 54 years. Cause of death:
disseminated lymphoma.
Gross examination: received fresh, a rectangle of
nasopharyngeal mucosa approximately 7 5 cm at¬
tached at one end to the sphenoid bone. The opening
of the eustachian tube, the tubal elevation and the
fossa of Rosenmiiller could be seen on the left side.
The right side was incomplete. Six representative
blocks were taken from the mucosa in the area of the
eustachian tube and fossa of Rosenmiiller (see figure
2). They were fixed in buffered formalin for 24
hours and processed to paraffin wax by a standard 18
hour schedule.
3.4.3. A87-371: male aged 76 years. Cause of death:
myocardial infarction.
Gross examination: received fresh, a rectangular
piece of nasopharyngeal mucosa approximately 55
cm, attached to the sphenoid bone. The opening of
the eustachian tube, the tubal elevation and the
fossa of Rosenmiiller could be seen on the left side.
The right side was incomplete. Five representative
blocks were taken from the area of eustachian tube
and the the fossa of Rosenmiiller (see figure 3).
They were fixed in buffered formalin for 24 hours
and processed to paraffin wax by a standard 18 hour
schedule.
3.4.4. A87-376: male aged 59 years. Cause of death:
carcinoma of lower oesophagus with secondaries of
the lung, liver and stomach.
Gross examination: received fresh, a diamond shaped
piece of nasopharyngeal mucosa approximately 6 4.5
cm, attached to the sphenoid bone. The opening of
the eustachian tube, the tubal elevation and the
fossa of Rosenmiiller could be seen on the left side.
The right side was incomplete. Two depressions 5mm
long were noted in the anterior right mucosa. Nine
blocks were taken from the mucosa in the area of the
eustachian tube and the fossa of Rosenmiiller (see
figure 4). They were fixed in buffered formalin for
24 hours and processed to paraffin wax by a standard
18 hour schedule.
All paraffin blocks were sectioned at 3-4 microns,
mounted on chrome alum-gelatine coated slides and baked
in a 56 °C oven overnight. The slides were stored in a
closed box at room temperature until used.
3.5. BIOPSIES OF NASOPHARYNX
3.5.1. INTRAEPITHELIAL LESIONS
46 paraffin processed biopsies of nasopharynx were
obtained from the histology files of the Department of
Morbid Anatomy, PWH. They had already been diagnosed and









They were sectioned at 2-3 microns, mounted on
chrome alum-gelatine coated slides and baked in a 56°C
oven overnight. They were stored at room temperature in a
closed box until used.
3.5.2. CARCINOMAS
31 paraffin processed biopsies were obtained from
the histology files of the Department of Morbid Anatomy,
PWH. They had already been diagnosed and classified by
the WHO system.71 They showed the following lesions:











They were sectioned at 2-3 microns, mounted on
chrome alum-gelatine coated slides and baked in a 56°C
oven overnight. They were stored at room temperature in a
closed box until used.
3. METHODS
3.6. MODIFIED ANTICOMPLEMENT IMMUNOFLUORESCENCE TEST
This procedure is detailed in appendix 3. This was
performed on the smears and paraffin sections of the Raji
and BJA-B cells, on frozen sections from the fresh biopsy
of NPC and on the paraffin sections of the xenografts
1216 and 1252. The rationale of the modification was to
apply the sensitive streptavidin-biotin technique to the
well established ACIF test.
The ACIF test has only been used on smears of cul
tured cells, impression smears from tumour biopsies and
frozen sections. it has not been used successfully on
paraffin processed tissues. Reasons for this lack of
success are not understood. It could be that the antigen,
EBNA, is partially or completely destroyed in the fixa¬
tion and processing procedure. It was thought that if it
were only partially destroyed, as is the case with many
antigens, a highly sensitive method such as the
streptavidin-biotin technique would localise small quan¬
tities of residual antigen.
In the ACIF test,59'122 smears from lymphoblastoid
cell lines, impression smears from Burkitt's lymphoma
biopsies or impression smears from NPC biopsies are
prepared, air dried and fixed in cold acetone or acetone-
methanol. Primary antisera are obtained from Burkitt's
lymphoma or NPC patients with raised titres to EBV an¬
tigens VCA, EA and EBNA, as determined by immunofluores¬
cence on Raji cell smears.224 Non-specific nuclear stain¬
ing is excluded by testing the sera on a T-cell line
which is free of EBV DNA and EBNA. Negative control serum
is anti-EBNA negative. Serum with no detectable EBV an¬
tibodies is used as a source of complement.
In the first step the smears are incubated with the
primary antiserum (which is first diluted optimally and
incubated at 56 °C for 30 min to inactivate complement)
together with complement in a humid chamber at 37°C. After
washing, the second step is an incubation with an op¬
timally diluted fluorescein conjugated rabbit anti human
complement. Slides are examined with a fluorescence
microscope.
When applied to cold acetone-methanol fixed impres
sion smears of NPC biopsies, the procedure has been
changed slightly by incubating in the primary antiserum
and the complement in two separate steps.59 In both tech¬
niques granular fluorescence is seen in the nuclei of the
positive cells, although the fluorescence in the cultured
cells is finer than that of the smears prepared from
biopsies.
In the modified ACIF method, step one was an incuba¬
tion in the primary antiserum, which was serum from NPC
patient 10290. The serum had been screened for EBV and
antinuclear antibodies and complement had been inac¬
tivated as described above. Step two was to apply
biotinylated anti human IgG, and step three a
streptavidin-biotin-complex which was conjugated to
preoxidase. The peroxidase was visualised with DAB-H202
(see appendix 1) which gave a brown insoluble deposit at
the site of reaction. Table 4 compares the ACIF and this
modification. Details of the modification are given in
appendix 3. The test was repeated using the primary an¬
tiserum at a variety of dilutions: 1:10, 1:20, 1:40,
1:80, 1:100, 1:200 and 1:400 to establish an optimum
dilution. The primary antiserum was omitted in negative
controls.
TABLE 4. MODIFIED ACIF TEST TO DEMONSTRATE EBNA
ACIF59'122 Modification
1. Incubate with optimally diluted anti EBNA

















3.7. HISTOLOGICAL AND HISTOCHEMICAL TECHNIQUES
The following technigues were performed on paraffin
sections from the autopsy cases and on the NP biopsies.
Details of the techniques are given in appendix 2.
3.7.1. HAEMATOXYLIN AND EOSIN
All sections were stained with Mayer's haematoxylin
and eosin.
3.7.2. SOUTHGATE'S MUCICARMINE 225
This is one of the early empirical techniques for
the demonstration of mucins. It uses a complex solution
which is specific for mucins, although neutral mucins and
some strongly sulphated mucins stain weakly or not at
all. Other acid mucins stain strongly. The staining
mechanism is not clearly understood but it is probable
that aluminium salts in the solution form a carmine-
mordant complex which bonds with the negatively charged
acid mucins.229'227
Southgate's mucicarmine was used to stain mucin in
all the autopsy specimens and the malignant biopsies of
nasopharynx. The method is given in appendix 2.
3.7.3. ALCIAN BLUE228
A copper phthalocyanine dye used in the textile in¬
dustry and first used as a biological stain by Steedman
in 1950.15 In 1957 the original alcian blue 8GS was re¬
placed by the new alcian blue 8GX. New improved staining
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procedures were worked out by Mowry. Alcian blue con¬
tains positively charged groups which will form ionic
bonds with some tissue polyanions. These polyanions are
the sulphate and carboxyl radicals af the acid mucins.
The staining of acid mucins by alcian blue is considered
to be specific. By varying the pH of the solution more
information can be obtained regarding the types of acid
mucins that are present. At pH 0.2 only the highly sul¬
phated mucins are ionised and react. At pH 1.0 both
weakly and strongly sulphated mucins react, while at pH
2.5 most acid mucins will stain. It must be noted,
however, that with these techniques, it is not always
possible to obtain clear cut demarcation of the different
15.226.227
types of mucin.''
Sections from all autopsy specimens, and from the
malignant biopsies of the nasopharynx were stained with
alcian blue at pH 1.0 and pH 2.5. Details of the methods
are in appendix 2.
3.7.4. PHLOXINE-TARTRAZINE230
A trichrome technique which was originally described
as a general histological stain which could be used for
the demonstration of inclusion bodies. It also
demonstrates fibrin, Paneth cells and keratin, when it is
stainable. It relies on overstaining with red phloxine,
followed by progressive substitution of the phloxine with
tartrazine in 2-ethoxyethanol which acts as a yellow
counterstain.
All sections from the autopsy specimens and the
malignant biopsies were stained with phloxine-tartrazine
for the demonstration of stainable keratin in the
epithelia. The method is given in appendix 2.
3.7.5. GORDON AND SWEETS' SILVER IMPREGNATION FOR
RETICULIN FIBRES231
Reticulin fibres (collagen type III) are fine
branching fibres which are normally found connected to
stronger and coarser collagen fibres. They make up a sup¬
porting framework in soft tissues such as liver, spleen
and lymph node, and are associated together with polysac¬
charides with basement membranes and basal laminae.
Reticulin fibres are best demonstrated with one of the
many silver impregnation techniques which give good con¬
trast. These methods are all modifications of the
Bielschowsky techniques for nerve fibres in which silver
from silver oxides is selectively deposited on the
fibres. It is then converted into visible reduced black
silver. Most reticulin techniques are preceded by a per¬
manganate oxidation step which probably prevents ar-
gyrophilia of nerve fibres. The final step is to remove
any remaining unreduced silver by treating with sodium
thiosulphate which prevents background precipitation, due
to light reduction226'227
Gordon and Sweets' technique is a popular and reli¬
able method which gives sharp black impregnation of the
reticulin fibres, collagen is orange-brown while the
background is clear. It was used on all autopsy specimens
and on all the malignant biopsies of nasopharynx, for the
demonstration of the basal laminae which separate the
epithelia from the underlying lamina propria. The
detailed method is given in appendix 2.
3.8. IMMUNOHISTOCHEMICAL TECHNIQUES
Sections were tested with three monoclonal antibody
preparations: AE1AE3 (Hybritech),232 Cytokeratin 18
(Amersham)233 and MA6 which was a gift from Professor M H
Ng, Department of Microbiology, University of Hong Kong.
Optimum dilutions and incubation times had to be es¬
tablished for each antibody, and for the linking
reagents.
3.8.1. DILUTIONS AND INCUBATION TIMES OF SECOND AND
THIRD IMMUNOREAGENTS
The second layer antibody for all three primary
monoclonal antibodies was a biotinylated rabbit anti
mouse immunoglobulins (Dakopatts).234 phis antibody had
been raised against a mouse serum pool, affinity purified
and biotinylated (product information). The third im
munoreagent was a streptavidin-biotin-peroxidase complex
(Amersham).233 Using AE1AE3, at a dilution of 1:150 for
30 min as the primary antibody, the biotinylated rabbit
anti mouse immunoglobulins (Igs) and the streptavidin-
biotin-peroxidase complex were set up in a series of
chequerboard titrations. Paraffin sections of buffered
formalin fixed carcinoma of oesophagus were used as con¬
trol material.
The first involved incubating with biotinylated rab¬
bit anti mouse Igs at dilutions of 1:200, 1:250, 1:300,
1:400 and 1:500 and in streptavidin-biotin-peroxidase
complex at dilutions of 1:100, 1:200, 1:300, 1:400 and
1:500 for 3 0 min each. All dilutions were prepared in
0.05M TBS pH 7.6 and all incubations were done in a humid
chamber at room temperature.
When the optimum dilutions were established a second
set of slides were stained, varying the staining times of
the second and third immunoreagents. Times of 30 min, 1
hour, 1 hour 30 min and 2 hours were used for both
reagents.
3.8.2. AE1AE3 ANTIBODIES (Hybritech
This is a mixture of two monoclonal antibodies which
were prepared against SDS—denatured human epidermal cal—
q 1-
lus keratins16 by the hybridoma technique. Culture
media from the hybridoma lines are used as a source of
antibodies.
AE1 is an IgG2a antibody which recognises a number
of cytokeratins of the acidic A subfamilv.












AE3 is an IgG2a antibody which recognises several
cytokeratins of the basic B subfamily.















The AE1AE3 antibody pool is supplied by the
manufacturer as a 20:1 mixture of AE1 to AE3. This com¬
bination is said to recognise all known epithelial
cytokeratins162 and has no known cross reactivities with
other cytoskeletal filaments.163'164
AE1AE3 was used in this investigation on paraffin
sections of all autopsy and biopsy specimens of
nasopharynx. A streptavidin-biotin-peroxidase
(Amersham)233 followed by DABH202 (see appendix 1)
visualisation procedure was used to locate the antigens.
Demonstration of cytokeratin in buffered formalin
fixed and paraffin processed tissue is enhanced with
preliminary treatment of sections with trypsin in order
to expose antigenically active binding sites. However,
the time of trypsinisation must be optimised for each
? i n
laboratory. Similarly, optimum dilutions and incuba¬
tion times of the primary antibody must be established. A
block of buffered formalin fixed, paraffin processed car¬
cinoma of oesophagus was used as control material.
To establish optimum trypsinisation time, sections
were treated with 0.1% trypsin with 0.1% calcium chloride
in 0.05M TBS, pH 7.8 at 37°C for 10, 15, 20, 25, 30, 40,
50, 60, 75, 90, 105 and 120 min. See appendix 1 for
details of trypsin preparation. The remainder of the
schedule was standardised as follows: AE1AE3 at 1:200
overnight; biotinylated rabbit anti mouse Igs at 1:250
for 30 min; streptavidin-biotin-peroxidase complex at
1:200 for 30 min.
For optimum dilution of AE1AE3 antibody, tryp-
sinised sections were incubated at room temp in a humid
chamber at dilutions of 1:100, 1:200, 1:300 and 1:400
for 30 min, 1 hour, 2 hours and overnight. The remainder
of the schedule was standardised at trypsin 1 hour;
biotinylated rabbit anti mouse at 1:250 for 30 min;
streptavidin-biotin-peroxidaes complex at 1:200 for 30
min. Dilutions were prepared in 0.05M TBS pH 7.6. A humid
chamber was used for all incubations. Non immune mouse
serum replaced the primary antibodies in negative con¬
trols. Details of procedures are given in appendix 3.
When optimum conditions had been established, sections
from autopsies and all biopsies were immunostained with
AE1AE3.
3.8.3. ANTI—CYTOKERATIN 18 (Amersham)23~
This monoclonal antibody was raised against the kid¬
ney epithelium cell line, PtKl. Cells were lysed in a
nonionic detergent (1% Nonidet P-40 in PBS pH 7.5). The
washed, centrifuged, insoluble material was sonicated and
used as the immunogen.235 Monoclonal antibodies were
prepared by the hybridoma technique.216 Among a number of
antibodies produced by this fusion, the IgG2a antibody,
LE6 5, was found by immunofluorescence to react with
simple epithelia, and by 2-dimensional 'Western1 blotting
to react with a 45Kd, pi 5.7 cytokeratin, or cytokeratin
18 by Moll's classification.159
poo
Anti cytokeratin 18 is supplied by Amersham as a
concentrated cell culture supernatant. Optimum conditions
for immunostaining were established by testing a section
of buffered formalin fixed, paraffin processed renal
biopsy. Trypsinisation (see appendix 1) times were op¬
timised by treating sections for 0, 10, 20, 30, 40, 50
and 60 min in trypsin, followed by immunostaining with
anti cytokeratin 18 diluted to 1:15 overnight. The an¬
tibody was diluted in PBS (0.15M NaCl plus 0.05M phos¬
phate buffer pH 7.2) containing 1% bovine serum albumin
(supplier's recommendation) at dilutions of 1:5, 1:10,
1:15 and 1:20 for two hours and overnight. Again all in¬
cubations were carried out in a humid chamber. Anti CK 18
was replaced by non immune mouse serum in negative con¬
trols. Details of procedures are given in appendix 3.
When optimum conditions had been established, sections
from autopsies and all biopsies were immunostained with
anti CK 18.
3.8.4. MA6 ANTIBODY
This antibody was a gift from Professor M H Ng,
Department of Microbiology, University of Hong Kong. See
section 2.8.2. for details of its production. It was sup¬
plied as a cell culture supernatant.
Optimum dilution was established by testing on sec¬
tions of buffered formalin fixed, paraffin processed
nasopharynx from autopsy. The antibody was diluted in
0.05M TBS pH 7.6 to 1:100, 1:150, 1:200, 1:250 and 1:300,
and incubated for 3 0 min, 1 hour, 2 hours and overnight
at room temp in a humid chamber. Non immune mouse serum
replaced MA6 in negative controls.
To try and eliminate non specific background stain¬
ing, sections were immunostained after trypsinisation
(see appendix 1) for 10, 20, 30, 40, 50 or 60 min. When
the optimum procedure was finalised, sections from
autopsies and the malignant biopsies were immunostained
with MA6 antibody. Details of the procedure are given in
appendix 3.
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Figure 4. STRUCTURE AND DISSECTION OF NASOPHARYNX A87-376










Smears of Raji cells showed brown granular staining
in the nuclei of cells fixed in acetone-methanol or in
buffered formalin. PLP-fixed cells were negative. The
pattern of staining was comparable with the granular
fluorescence seen in the ACIF test. Optimum nuclear
staining, with minimal cytoplasmic staining was seen with
the primary antiserum, 10290, diluted to 1:200 or 1:400.
Acetone-methanol gave better morphological preservation
than buffered formalin. BJA-B cell smears were uniformly
negative.
4.1.2. CELij SECTIONS
Sections of Ra j i cells showed brown granular stain¬
ing in the nuclei of cells fixed in acetone-methanol or
in buffered formalin. See figure 9. PLP-fixed cells were
again negative. Optimal dilution of primary antiserum
10290 was again between 1:200 and 1:400. BJA-B cells were
negative.
4.1.3 XENOGRAFTS
Variations of dilutions and incubation times gave no
staining of the paraffin sections from both xenografts.
4.1.4. BIOPSY OF NPC
The modified ACIF gave no nuclear staining, but many
lymphocytes and plasma cells had brown cytoplasmic stain
ing.
4.2. OPTIMISING IMMUNOHISTOCHEMISTRY PROTOCOLS
4.2.1. DILUTIONS AND INCUBATION TIMES OF SECOND AND THIRD
IMMUNOREAGENTS
Chequerboard titrations for optimum dilutions of
biotinylated rabbit anti mouse Igs (B-RAM) and
streptavidin-biotin-peroxidase complex (Stra-B-C). Op¬
timum staining was achieved when B-RAM was diluted to
1:250 and Stra-B-C to between 1:200 and 1:400. Lower
dilutions resulted in background staining while higher
dilutions gave weak staining. See table 5.
A similar titration for incubation times indicated
that prolonging incubation times over 30 min did not sig¬
nificantly improve demonstration of cytokeratin. Incuba¬
tion times of 30 min were therefore adopted for both
reagents.
4.2.2. TRYPSIN INCUBATION TIME WITH AE1AE3 ANTIBODIES
Trypsinisation. Optimum staining was achieved if
sections were treated with trypsin for between 1 hour and
1 hour 30 min prior to immunostaining. Times in excess of
1 hour tended to cause sections to become detached from
the slides, so a time of 1 hour was adopted.
4.2.3. DILUTION AND INCUBATION TIME OF AE1AE3
AE1AE3. A final chequerboard titration resulted in
overnight incubation with AE1AE3 diluted to between
1:200 and 1:400 giving best results. See table 6.
4.2.4. TRYPSIN INCUBATION TIME WITH ANTI-CYTOKERATIN 18
Using the renal biopsy as control material, 20 mil
trypsinisation gave the best results with heaviest stain
ing in the distal convoluted tubules.
4.2.5. DILUTION AND INCUBATION TIME OF CYTOKERATIN 18
The chequerboard titration resulted in optimum
staining at dilutions of 1:5, 1:10 or 1:15 overnight. Be¬
cause of the expense of anti CK 18, a 1:15 dilution was
adopted for all tests. Results are summarised in table 7.
4.2.6. DILUTION, INCUBATION TIME AND TRYPSIN INCUBATION
WITH MA6 ANTIBODY
The conditions which gave the least background
staining were a 1:300 dilution of MA6 and an overnight
incubation.
Because MA6 tended to give non specific staining, it
was found that after 2 0 min treatment with trypsin prior
to immunostaining, staining was more distinct and back¬
ground staining was reduced.
4.3. AUTOPSY TISSUE
4.3.1. HISTOLOGY
Microscopic examination of haematoxylin and eosin
stained sections of A86—76 showed the epithelia which
were separated from the lamina propria by the basal
lamina. Throughout the lamina propria, mixed mucous and
serous glands could be seen, occasionally with ducts
leading to the epithelial surface. Lymphoid tissue was
present throughout the anterior 23 of the specimen, lio
lymphoid follicles were identified. The tubal elevation
was cartilaginous and covered by a thin layer of columnar
or intermediate epithelium.
The anterior part of the nasopharynx was covered by
pseudostratified ciliated columnar epithelium which ex¬
tended over the area corresponding with the roof. Around
the area of the openings of the eustachian tubes, the
tubal elevations and the fossae of Rosenmiiller, the
columnar epithelium merged with intermediate epithelium
which formed a wavy strip across the entire specimen.
Towards the posterior third, that is the oral end of the
nasopharynx, the intermediate epithelium gave way to
stratified squamous epithelium. The divisions between the
intermediate and the columnar and squamous epithelia were
not distinct. There were always patches of each type of
epithelium in the areas of the divisions. Figure 5 shows
the distribution of epithelium in A86-76.
Specimens A87-368, A87-371 and A87-376 were taken to
look closely at the histology and immunohistochemistry of
the epithelia around the fossae of Rosenmiiller, the tubal
elevations and the eustachian openings, because it is in
this region that the largest proportion of carcinomas are
reported to arise. Although the exact distribution of
epithelia varied from case to case, the anterior part was
always covered by pseudostratified columnar epithelium
and the posterior with stratified squamous epithelium.
The area around the eustachian openings, the fossae of
Rosenmuller and the tubal elevations in all four cases
was pseudostratified ciliated columnar or intermediate
epithelium or a mixture of both. See figures 6, 7 and 8
for diagrams of the distribution of epithelia in these
autopsy specimens.
The three types of epithelium could be distinguished as
follows:
Stratified squamous: six or seven or more layers
thick. The basal cells, adjacent to the basal
lamina, were cuboidal. The more mature cells nearer
the epithelial surface were flattened, their nuclei
became small and pyknotic and the relative amount of
cytoplasm increased. See figure 10.
Pseudostratified ciliated columnar: elongated cells
with many mucin producing goblet cells- some areas
had more goblet cells than others. The cell borders
were always ciliated. See figures 11 and 12.
Intermediate: stratified into six or seven layers,
the cells were cuboidal with virtually no flattening
towards the surface and the nuclear size remained
constant. Occasional remnants of goblet cells were
seen. See figures 13 and 14.
4.3.2. HISTOCHEMISTRY
Mucin stains: Southgate's mucicarmine stained the
acid mucins in the submucosal mucous glands and in the
goblet cells of the pseudostratified ciliated columnar
epithelium as illustrated in figure 12. Occasional goblet
cells seen in the intermediate epithelium were also
stained. Alcian blue stained more heavily at pH 2.5 than
at pH 1.0, indicating an excess of acid over sulphated
mucins in both the submucosal mucous glands and the
epithelial goblet cells.
The phloxine tartrazine method is a useful general
tissue stain. In the submucosa the collagen stained yel¬
low and muscle red. Occasional patches of keratin in the
squamous epithelium were phloxinophilic.
Gordon and Sweets' reticulin method clearly outlined
the basal lamina which always forms the division between
the epithelium and the submucosa. Reticulin was
demonstrated as fine black fibres and collagen as coarse
orange-brown fibres.
4.3.3. IMMUNOHISTOCHEMISTRY
MA6 staining of epithelium gave variable results.
All three epithelial types would sometimes stain
moderately and at other times would be negative. Mucous
and serous glands were usually positive, as were myelin
and striated muscle. Lymphocytes stained consistently
strongly. Figure 15 shows MA6 staining of a section of
columnar epithelium. Only the lymphocytes in the lamina
propria are distinctly stained.
A86-76 was received after several weeks fixation in
buffered formalin. Such prolonged fixation made it dif¬
ficult to demonstrate cytokeratin consistently even after
diastase digestion. The three later autopsy specimens of
nasopharynx, A87-368, A87-371, and A87-376 were fixed for
only 24 hours thus avoiding the 'over fixation' seen in
A86-76.
AE1AE3 stained the pseudostratified columnar
epithelium strongly and the intermediate epithelium
moderately. The basal cells and deeper third of the
squamous epithelium stained, while the middle and upper
thirds were negative. This is illustrated in figures 16
and 17. The simple cuboidal epithelium of the serous
glands stained moderately strongly and of the mucous
glands, weakly.
Immunostaining of stratified squamous and inter¬
mediate epithelium were both negative with anti
cytokeratin 18. See figure 18. Columnar epithelium
stained strongly with anti cytokeratin 18, but only in
the upper parts of the cells. The intermediate and lower
parts stained weakly or were negative. See figure 19.
Table 8 summarises the results or immunostaining me




The various types of intraepithelial change seen in
the 46 biopsies were often confined to small patches of
epithelium which were surrounded by relatively normal
epithelial tissue.
Immunostaining with AE1AE3 antibodies gave the most
interesting results. The general trend in these biopsies
was that those areas showing intraepithelial changes
stained less heavily than their adjacent more normal
epithelia. Because of the heterogeneity of each biopsy,
internal controls of normal epithelium could usually be
found within each section so that comparisons of staining
intensities could be made.
Patches of sguamous metaplasia were always stained
less strongly than the surrounding normal epithelium,
whether it was columnar or intermediate. See figure 20.
Squamous metaplasia may be difficult to identify in
haematoxylin-eosin stained sections, as illustrated in
figure 21, whereas with AE1AE3 staining those areas can
be seen fairly easily as in figure 22.
All hyperplastic epithelia stained less intensely
than their normal counterparts.
Cells showing koilocytic change could be identified
quite easily in haematoxylin—eosin sections (see figure
23) by their vacuolated cytoplasm and perinuclear halo.
With AE1AE3 the cytoplasm of these cells was unstained.
See figure 24.
Those areas showing intraepithelial neoplasia were
again less strongly stained with AE1AE3 than the sur¬
rounding more normal epithelium although it was not pos¬
sible to distinguish with any accuracy between
nasopharyngeal intraepithelial neoplasia grades I, II and
III by this method. See figure 25.
These results are summarised in table 9.
4.5. CARCINOMAS
4.5.1. HISTOCHEMISTRY
None of the carcinomas showed evidence of mucin
production. The squamous cell carcinoma was encapsulated
by reticulin fibres, as were 14 out of 27 undifferen¬
tiated carcinomas. See figure 26.
Phloxine tartrazine technique stained keratin red
where it was present in large quantities in the case of
keratinising squamous cell carcinoma. (See figures 27 and
28). Otherwise, phloxine tartrazine proved to be a good
trichrome technique which would demonstrate tumour cells
grey-blue clearly against the dark blue lymphocytes and
yellow connective tissue (see figure 29), often more
clearly than haematoxylin-eosin stained sections (figure
30).
4.5.2. IMMUNOHISTOCHEMISTRY
MA6 antibody gave variable results. Some tumours
stained weakly and some showed moderately strong stain¬
ing. However in all preparations there was some non
specific background staining, even after treatment with
trypsin prior to immunostaining. The antibody cross
reacted with other tissue components besides tumour
cells, such as myelin, striated muscle, lymphocytes and
plasma cells which often made it difficult to identify
the tumour cells. See figure 31.
AE1AE3 stained the squamous cell carcinoma quite
distinctly as in figure 32. Of the undifferentiated car¬
cinomas, 26 out of 27 were positive with AE1AE3. Ex¬
amples are shown in figures 33 and 34. In biopsies where
normal epithelia were available as internal controls, the
tumour cells stained less densely than the normal
tissues.
All of the carcinomas were negative with anti-
cytokeratin 18.
A summary of the results of immunohistochemistry of
the carcinomas is given in Table 10.
Figure 5. DISTRIBUTION OF NASOPHARYNGEAL EPITHELIA A86-76
KEY
Pseudostratified ciliated columnar epithelium
Intermediate epithelium
Stratified squamous epithelium
Figure 6. DISTRIBUTION OF NASOPHARYNGEAL EPITHELIA A87-368
KEY
Pseudost.rat.ified ciliated columnar epithelium
Intermediate epithelium
Stratified squamous epithelium
Figure 7. DISTRIBUTION OF NASOPHARYNGEAL EPITHELIA A87-371
KEY
Pseudostratified ciliated columnar epithelium
Intermediate epithelium
Stratified squamous epithelium
Figure 8. DISTRIBUTION OF NASOPHARYNGEAL EPITHELIA A87-376
KEY
Pseudostratified ciliated columnar epithelium
Intermediate epithelium
Stratified squamous epithelium
TABLE 5. CHEQUERBOARD TITRATION FOR OPTIMUM DILUTIONS OF
BIOTINYLATED RABBIT ANTI MOUSE AND STREPTAVIDIN-BIOTIN-
PEROXIDASE.
B-RAM
















B-RAM= biotinylated rabbit anti mouse Igs
Stra-B-Px= streptavidin-biotin-peroxidase
Control tissue: buffered formalin fixed paraffin
section of oesophageal carcinoma
Trypsin incubation time: 1 hour
Primary antibody: AE1AE3 1:150 for 30 min
Intensity of staining: weak, medium,
strong
denotes background staining.
TABLE 6. AE1AE3 OPTIMUM DILUTION AND INCUBATION TIME












Control tissue: buffered formalin fixed paraffin
section of oesophageal carcinoma
Trypsin incubation time: 1 hour
Biotinylated rabbit anti mouse: 1:250 for 30 min
Streptavidin-biotin-peroxidase: 1:200 for 30 min
Intensity of staining:+= weak,++= medium,
+++= strong.
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B-RAM= biotinylated rabbit anti mouse Igs
Stra-B-Px= streptavidin-biotin-peroxidase
Control tissue: buffered formalin fixed paraffin
section of oesophageal carcinoma
Trypsin incubation time: 1 hour
Primary antibody: AE1AE3 1:150 for 30 min




TABLE 6. AE1AE3 OPTIMUM DILUTION AND INCUBATION TIME












Control tissue: buffered formalin fixed paraffii
section of oesophageal carcinoma
Trypsin incubation time: 1 hour
Biotinylated rabbit anti mouse: 1:250 for 30 min
Streptavidin-biotin-peroxidase: 1:200 for 30 min
Intensity of staining:+= weak,++= medium,
strong.
TABLE 7. ANTI-CYTOKERATIN 18 OPTIMUM DILUTION AND
INCUBATION TIME












Control tissue: buffered formalin fixed paraffin
section of renal biopsy
Trypsin incubation time: 20 min
Biotinylated rabbit anti mouse: 1:250 for 30 min
Streptavidin-biotin-peroxidase: 1:200 for 30 min
Intensity of staining:+= weak,++= medium,
+++= strong.



















Lower third stains only. Middle and upper thirds
negative.
Upper parts of cells stain only. Middle and lower
parts weak or negative.
NOTES:
1. MA6 also stained other tissues including lym¬
phocytes, plasma cells, myelin and striated muscle.
2. Intensity of staining: negative, variable,
weak, medium, strong.
TABLE 9. IMMUNOHISTOCHEMISTRY OF INTRAEPITHELIAL LESIONS






AE1AE3 always stained less intensely than in nomal
epithelia.
Cytokeratin 18 was positive only with columnar
epithelium.
NOTES:
1. NPIN= nasopharyngeal intraepithelial neoplasia.
2. Intensity of staining:-= negative,++- medium.
TABLE 10. IMMUNOHISTOCHEMISTRY OF CARCINOMAS






= AE1AE3 always stained less intensely than associated
normal eoithelia.
CK 18= anti cytokeratin 18
SCC= squamous cell carcinoma
UC= undifferentiated nasopharyngeal carcinoma,
5. DISCUSSION
Preliminary work with the modification of the an-
ticomplement (ACIF) test for EBNA was reasonably success¬
ful. Smears of Raj i cells fixed in acetone-methanol and
buffered formalin showed brown granular staining in the
nuclei which was comparable with the fluorescence pattern
seen in the ACIF test. Non specific cytoplasmic staining
was minimal when the primary antiserum was diluted to
1:200 or 1:400. Periodate-lysine-paraformaldehyde (PLP)
fixed smears were negative.
Sections of the pelleted Raji cells fixed briefly (1
hour) and routinely processed to paraffin wax also showed
positive granular staining in cell nuclei of those fixed
in acetone-methanol and buffered formalin. This
granularity was taken to be EBNA. Morphological preserva¬
tion was much better in the acetone-methanol fixed cells
than those fixed in buffered formalin. Again the PLP-
fixed cells were negative. PLP is a fixative that has
been used for immunoelectron microscopy and for im-
munohistochemistry of nervous tissue. It was
therefore surprising that the cells were completely nega¬
tive for EBNA after fixation with it.
The positive results with the sections of acetone-
methanol or buffered formalin fixed and paraffin
processed Raj i cells indicated that what was assumed to
be EBNA in the smears had not been destroyed by longer
fixation and the paraffin processing schedule.
The xenograft, however, failed to give any positive
staining. Time was spent modifying the procedure by al
tering dilutions and incubation times, but results were
consistently negative.
The nuclei of the tumour cells were negative in the
frozen sections from an NPC case but some lymphocytes
stained strongly. This was attributed to the second layer
immunoreagent, a rabbit anti human IgG, which reacted
with anti EBNA antibodies in the primary antiserum.
Naturally the anti human IgG reacted with any IgG-
containing plasma cells and lymphocytes. It was decided
that the ACIF modification in this form would not be
easily applicable to paraffin processed biopsy material
as there is no reliable way of blocking IgG-containing
plasma cells and because tumour cells in the xenograft
and the frozen section had not stained. The antiserum may
have lacked the high titre and avidity necessary for
successful immunohistochemistry on paraffin sections. It
is possible that the extended fixation time of six hours
plus the paraffin processing may have altered the an¬
tibody binding site of EBNA.
The next stage of the investigation was a retrospec¬
tive histochemical and immunohistochemical study of the
epithelium of the normal nasopharynx and of nasopharyn¬
geal biopsies which showed intraepithelial changes and
malignancies.
Histology of four autopsy specimens of nasopharynx
confirmed Ali's early study of the histology of the
nasopharyngeal epithelium. The anterior part (the nasal
end) is covered with stratified sguamous epithelium while
the posterior part (the oral end) has a covering of pseu-
dostratified columnar epithelium. At the junction of
these two epithelial types is a distinct zone of inter¬
mediate epithelium. This epithelium is stratified into 6
or 8 layers. All the cells are cuboidal, they do not ma¬
ture into the flattened cells seen in the stratified
squamous epithelium. Intermediate epithelium covers the
area around the Eustachian openings and the fossae of
Rosenmuller and the upper part of the salpingopharyngeal
folds. These areas have been noted in many studies to be
common sites of origin of NPC.2'10'13
Results of Southgate's stain indicated that all the
mucins in both the epithelium and the lamina propria are
acid mucins. By staining with alcian blue at varying pH
it is possible to roughly distinguish between sulphated
(which stain at pH 1.0) and acid (which stain at pH 2.5)
mucins. Alcian blue staining in this study stained more
heavily at pH 2.5 than at pH 1.0, suggesting an excess of
acid over sulphated mucins in the epithelium and the
lamina propria. This confirmed Tock and Tan's118 more
detailed study of the mucins of the nasopharynx. They
found more sialidase resistant sialomucins (sialomucins
are among the group of acid mucins) than sulphated
mucins.
None of the tumours were mucin producing, so
demonstration of mucins would not generally be a useful
aid to diagnosis of malignancies.
Phloxine tartrazine stain demonstrated occasional
patches of keratin in squamous epithelium where it was
present in large enough quantities to be stained.
Phloxine tartrazine was found to be a useful trichrome
technique, demonstrating tumour cells grey-blue against
the dark blue lymphocytes and yellow stroma.
Silver impregnation for reticulin fibres clearly
showed the basal laminae. Some of the tumour biopsies
showed islets of tumour cells that were encapsulated by
reticulin fibres. Liang suggested that those tumours
showing encapsulation tended to be well differentiated
and did not invade and metastasise, while those without
encapsulation were poorly differentiated and more
frequently invaded the cranial base and metastasised.
The immunogen for MA6 antibody was an im-
munoprecipitate obtained by counterimmunoelectrophoresis
of serum from an NPC patient against an extract of lysed
Raji cells. The purpose of using this immunogen may have
been to try and produce an antibody against one of the
EBV antigens. MA6 has been identified to react with a
55Kd glycoprotein called B-lymphocyte carcinoma cross-
reacting antigen (BLCa). BLCa has turned out to be an an¬
tigen which is widely distributed in tissues. It occurs
on B-lymphocytes as well as on carcinomas including
NPC.174 This study showed that MA6 also reacted with
several other sites including squamous epithelium,
myelin, muscle and blood vessels.
MA6 did not stain the NPC cells with sufficient in¬
tensity or selectivity to be useful as a tumour marker.
B-lymphocytes were most heavily demonstrated. NPCs are
often associated with a heavy lymphocyte infiltrate,
which, if stained with MA6, could obscure small foci of
tumour cells.
It has already been shown that immunohistochemical
identification of cytokeratin is so far the most reliable
means of distinguishing NPC from other tumours of the
area of the nasopharynx. The next part of the study in¬
volved the immunolocalisation of cytokeratin in the
tissues under study.
AE1AE3 is a 'broad spectrum' anti cytokeratin. Its
suppliers, Hybritech, claim it will demonstrate all types
of epithelium. Distinct and reproducible patterns of
reactivity with both normal and abnormal nasopharyngeal
tissues emerged. Pseudostratified columnar epithelium
stained more intensely than intermediate epithelium which
in turn stained more heavily than stratified squamous
epithelium. Only the basal cells of stratified squamous
epithelium tended to stain, while the middle and upper
layers were unstained.
Hyperplastic epithelium of all types stained posi¬
tively with AE1AE3. Areas of squamous metaplasia stained
less intensely than the surrounding more normal
epithelium, which was often intermediate epithelium.
Small patches of squamous metaplasia can be difficult to
identify in haematoxylin-eosin stained sections, so
staininq with AE1AE3 could be a useful aid for its iden¬
tification. Certain carcinomas are believed to arise from
within areas of squamous metaplasia, for example squamous
101
carcinoma of the bronchus. Whether or not squamous
metaplasia in the nasopharynx is a precursor to carcinoma
is not known.
The squamous and intermediate epithelium of the
nasopharynx occasionally shows cells with a similar ap¬
pearance to the koilocytes which have been described in
other sites and have been attributed to viral infec¬
tions.102'103,104,105'106 These cells have a prominent
nucleolus, a perinuclear halo and vacuolated cytoplasm,
but a viral association in the nasopharynx has not been
confirmed. In this study, koilocyte cytoplasm was clearly
unstained with AE1AE3. The cells were easily identifi¬
able, particularly in intermediate epithelium, where the
surroundinq unaffected cells were quite darkly stained
with AE1AE3.
Areas of intraepithelial neoplasia stained less in
tensely than adjacent normal epithelium. It was difficult
to identify a distinct pattern of reactivity with
nasopharynqeal intraepithelial neoplasia, but in qeneral,
the deqree of staininq decreased with the increasinq
severity of the neoplastic change.
Twenty-seven out of twenty-eight carcinomas stained
positively with AE1AE3. Staining intensities varied, but
using adjacent normal epithelia where available, as in¬
ternal controls, the tumour cells tended to stain less
intensely than the normal epithelia. The one specimen of
squamous cell carcinoma showed variable staining inten¬
sities within the tumour itself. Well differentiated
areas of tumour were less intensely stained than compara¬
tively undifferentiated areas. A parallel may be drawn
between these appearances with AE1AE3 and those of nor¬
mal squamous epithelium, where the well differentiated
upper layers of squamous cells stain less intensely than
the relatively undifferentiated deeper layers.
Cytokeratin 18 is one of the low molecular weight
(45Kd) cytokeratin proteins which occurs only in simple
epithelia. In this investigation, anti-cytokeratin 18
reacted only with the upper parts of pseudostratified
columnar epithelial cells. This is in concurrence with an
investigation of the cytokeratins of the epithelium of
o o T
the upper respiratory tract by Nagle et al. using a
murine monoclonal antibody, RGE-53, which reacts with
cytokeratin 18. Immunofluorescence studies of the
nasopharynx showed the same pattern of reactivity with
the pseudostratified columnar epithelium as in this
study. The cuboidal epithelium of mucous and serous
glands in the lamina propria was also positive. These are
all simple epithelia. The more complex intermediate and
stratified squamous epithelia did not stain with anti-
cytokeratin 18. Areas of hyperplastic columnar epithelium
were demonstrated, but all other intraepithelial lesions
were unstained. Cytokeratin 18 was negative with all car
cinomas.
This study has been an attempt to define the
epithelial cell populations of the nasopharynx by his-
tochemical means. The conventional histochemical methods
confirmed the results of several earlier studies, on the
type and distribution of mucins and the distribution ol
reticulin fibres. Such histochemistry has not been able
to solve the problems of histological classification anc
histogenesis of the tumours.
Immunohistochemistry has shown that it may be pos¬
sible to define the nasopharyngeal epithelia by identify¬
ing suitable antigen markers within the tissue.
MA6 antibody, which identifies the widely dis¬
tributed BLCa antigen, is probably not specific enough a
marker for epithelia or for nasopharyngeal carcinoma
cells to be of use in such a study.
AE1AE3 is a useful broad spectrum immunoreagen
for the recognition of epithelial cells and epithelia
derived tumours. The cytoplasm of koilocytes wa
unstained. It stained all but one of the NPCs in th
study. It identified areas of squamous metaplasia, whic
may in future prove to be of diagnostic significance i
NPC if the role of squamous metaplasia in the nasopharyn
is established and it also stained intraepithelia
neoplasia. Overall, AE1AE3 stained all normal epitheli
more heavily than those that were undergoing pathologica
changes, both benign and malignant, which indicates tha
the total expression of cytokeratins is reduced in abnor
mal epithelia.
CK 18 only stained the tips of the columnar cells.
It was negative with all of the tumours. It is known that
some carcinomas express cytokeratin subsets that are very
similar to their normal precursor cells, for example,
adenocarcinoma of colon. Others, such as breast cancers
produce a subset which is different from the correspond¬
ing normal tissues.165'167 it is not known whether those
cytokeratins produced by NPC cells are the same or dif¬
ferent to those produced by the precursor epithelial
cells.
If NPC were known to express the same cytokeratin
subset as its cells of origin, then the negative results
with anti-cytokeratin 18 would indicate that the tumours
do not arise from the columnar epithelium. Conversely, if
the cytokeratin subset is different in the normal
epithelial cells than in the tumour cells, then these
results do not help to answer the question of the his¬
togenesis of NPC.
Further study of cytokeratin expression by the
nasopharyngeal epithelium may help to establish the
precursor cell type of NPC. If it were possible to estab¬
lish the cytokeratin subsets expressed by each of the
epithelial types and by the carcinomas, then comparisons
of these subsets may give an indication of the cell or
cells of origin of the tumours. However, as has been sug¬
gested by Batsakis et al,10 the intermediate epithelium
provides the original cell, the composition of the
cytokeratins of intermediate cells could well show a com¬
bination of the subsets seen in the stratified squamous
and the columnar epithelium. This has been shown to be
the case with other 'unusual' epithelia, such as the
transitional epithelium of the bladder and tracheal pseu-
dostratified columnar epithelium.162'166 Intermediate
epithelium would have no well defined cytokeratin charac-
teristics for comparison with those of the carcinomas. At
present, the functional significance of the complex dis
3
tribution of cytokeratins is unclear.
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APPENDIX 1
MISCELLANEOUS FIXATIVES, SOLUTIONS AND BUFFERS
1. PERIODATE-LYSINE-PARAFORMALDEHYDE FIXATIVE220'221
Stock reagents:
A. Lysine Phosphate Buffer
To 0.2M lysine-HCl add 0. 1M dibasic sodium
phosphate until pH= 7.4. Dilute with 0. 1M
sodium phosphate buffer, pH 7.4 to make 0. 1M
lysine.
B. Paraformaldehyde
Dissolve, with heat, 8g paraformaldehyde in
100ml water. Add a few drops of 10% sodium
hydroxide.





Make up to 100ml with distilled water. pH drops from
7.4 to 6.2. 3mm tissue blocks can be fixed without
pH adjustment at 4°C for 3 hours.
2. BUFFERED FORMALIN
10ml formalin (40% HCHO)
0.4g sodium phosphate, monobasic
0.65g sodium phosphate, dibasic
Make up to 100ml with distilled water.
3. ACETONE-METHANOL
Prepare fresh each time.
Equal volumes of fresh acetone and methanol,
4. CHROME ALUM-GELATINE COATED SLIDES222
1. Dissolve 3.Og gelatine in 1 litre distilled
water, heated to approx 60°C
2. Add 0. 5g chromium potassium sulphate (chrome
alum). The solution will turn blue
3. Add several thymol crystals
4. Filter a small portion while hot into a 100ml
beaker, keeping the stock hot
5. Place several slides, one at a time, into the
beaker
6. When slides are dry, collect and store at room
temperature in a slide box.




5 litres distilled water
For Use:
Make a 1:10 dilution in distilled water. Adjust pH
to between 7.1 and 7.4.








1 litre distilled water
For Use: Make a 1:10 dilution in distilled water,




24.2g Tris (hydroxysethyl) methylamine
1 litre distilled water
B. 0.2M HC1:
17ml conc. HC1
1 litre distilled water
For Use:
250ml A+ 192ml B. Make up to 1 litre with distilled
water.
8. diaminobenzidine-h2o2 (DAB-H202)
Peroxidase substrate. Prepare fresh each time.
50mg diaminobenzidine tetrahydrochloride (Sigma212)
100ml 0.05M Tris-HCl buffer, pH 7.6
Just before use, add 0.05ml fresh 1% H2C2.
9. TRYPSIN210'211
This solution should be prepared immediately before
use and not re-used. The solution and the slides
should be warmed to 37°C before use.
212
0.lg trypsin (pancreatic type II, Sigma)
100ml 0.1% CaCl2












1 litre distilled water
Dissolve in order. Boil for 5 mins. Cool and filter.
APPENDIX 2
HISTOLOGICAL AND HISTOCHEMICAL TECHNIQUES








Take sections to water
Stain in Mayer's haematoxylin, 5 min
Wash and blue in running tapwater, 5 min
Counterstain in 1% aqueous eosin, 3 min
Rinse quickly in tapwater
Dehydrate in alcohol, clear in xylene and mount
in synthetic resin.
Results:
Nuclei- blue; cytoplasm, red blood cells,
muscle, collagen- shades of pink and red.
2. SOUTHGATE'S MUCICARMINE2 2 5
Preparation of Stain:
Grind lg carmine and place in a large conical flask.
Add 100ml 50% alcohol and mix. Add lg aluminium
hydroxide, mix, and add 0„5g anhydrous aluminium









Take sections to water
Stain in Mayer's haematoxylin for 5 min
Wash and blue in running tapwater
Stain with mucicarmine for 20 min
Wash in distilled water
Dehydrate in alcohol, clear in xylene and mount
in synthetic resin.
Results:
Nuclei- blue; mucins-- red.





















Take sections to water
Stain with appropriate filtered alcian blue
solution, 10 min
Wash in running water, 5 min
Stain nuclei in 0.25% acid fuchsin in 1% acetic
acid, 30 sec
Rinse quickly in distilled water
Dehydrate in alcohol, clear in xylene and mount
in synthetic resin.
Results:
At pH 2.5: nuclei- red; weakly acid sulphated
mucins- blue; sulphated mucins stain weakly or
not at all.
At pH 1.0: nuclei~ red; sulphated mucins-
blue; acid mucins stain weakly or not at all.







Saturated solution of tartrazine in 2-ethoxyethanol
Method:
1. Take sections to water
2. Stain in Mayer's haematoxylin, 5 min
3. Wash and blue in running tapwater
4. Stain in phloxine, 20 min
5. Rinse in water, then in 2-ethoxyethanol
6. Stain in tartrazine, checking with microscope
until only red blood cells are strongly stained
with phloxine
7. Wash in 2-ethoxyethanol
8. Clear in xylene and mount in synthetic resin.
Results:
Nuclei- blue; red blood cells- bright red; muscle
and keratin- red; other tissues- yellow.




47.5ml 0.25% potassium permanganate
2.5ml 3% sulphuric acid
Ammoniacal silver:
To 5ml 10% silver nitrate add cone ammonia drop by-
drop with frequent mixing until the formed
precipitate just redissolves. Add 5ml of 3.1% sodium
hydroxide and mix. A precipitate will form which
gradually dissolves upon the addition of ammonia,
drop by drop as before. Stop when there only a few
precipitate granules remaining. Make up the final












Take sections to water
Treat with acidified permanganate, 5 min
Wash off and bleach with 5% oxalic acid
Rinse in distilled water-
Treat with 3% ferric ammonium sulphate, 5 min
Wash well in distilled water
Treat with ammoniacal silver, 4-5 sec
Wash well in distilled water
Reduce in 10% formalin in tapwater, 30 sec
Wash and treat with 5% sodium thiosulphate, 3
min






















Take sections to water and rinse in phosphate
buffered saline (PBS)(see appendix 1) or bring
smears to room temp and rinse in PBS
Block endogenous peroxidase activity (if
necessary) with fresh 3% H202 in methanol
Wash in PBS and incubate with primary antiserum
diluted to 1:100 at 37C,C for 60 min
Wash in 3 changes of PBS over 5 min
Incubate with biotinylated goat anti human IgG
diluted 1:200 at room temp for 30 min
Wash in 3 changes of PBS over 5 min
Incubate with streptavidin-biotin-peroxidase,
diluted 1:200 for 45 min
Wash in 3 changes of PBS over 5 min
Develop peroxidase in DAB-H202 for 5-10 min or
until optimum staining is achieved (see appen¬
dix 1)
Wash in tapwater
Stain nuclei in Mayer's haematoxylin, 30 sec
Wash and blue in running tapwater
Dehydrate in alcohol, clear in xylene and mount
in synthetic resin.
A positive result is shown by brown staining.
All dilutions are prepared in PBS with 1% normal
goat serum.
Negative controls:
1. Replace primary antiserum with serum which is
negative for EBV antibodies (step 3)
2. Omit secondary antibody (step 5)
2. IMMUNOSTAINING WITH AE1AE32 32
1. Take sections to absolute alcohol
2. Block endogenous peroxidase activity in 3% H202
in methanol
3. Wash in 0.05M Tris buffered saline pH 7.6
(TBS)(see appendix 2)
4. Treat with trypsin at 37 °C for 1 hour (see ap¬
pendix 1)
5. Wash in 3 changes of TBS over 5 min
6. Incubate in AE1AE3 diluted 1:300 overnight at
room temp
7. Wash in 3 changes of TBS over 5 min
8. Incubate in biotinylated rabbit anti mouse Igs
diluted 1:250 for 30 min
9. Wash in 3 changes of TBS over 5 min
10. Incubate in streptavidin-biotin-peroxidase,
diluted 1:200 for 30 min
11. Wash in 3 chancres of TBS over 5 min
12. Develop peroxidase in DAB-H202 (see appendix
1), for 5-10 min, checking microscopically
until optimum staining is achieved
13. Wash in tapwater
14. Stain nuclei in Mayer's haematoxylin, 1 mir
15. Wash and blue in running tapwater
16. Dehydrate in alcohol, clear in xylene and mount
in synthetic resin.
A positive result is shown by brown staining.
All dilutions are prepared in TBS and all incuba¬
tions are carried out at room temperature.
Negative control:
Replace primary antibody with non-immune mouse serum
(step 6).
3. IMMUNOSTAINING WITH ANTI-CYTOKERATIN 18233
1. Take sections to absolute alcohol
2. Block endogenous peroxidase activity in 3%
in methanol
3. Wash in 0.05M Tris buffered saline pH 7.6
(TBS)(see appendix 1)
4. Treat with trypsin (see appendix 1) at 37°C for
2 0 min
5. Wash in 3 changes of TBS over 5 min
6. Incubate in anti CK 18, diluted 1:15 overnight
7. Wash in 3 changes of TBS over 5 min
8. Incubate in biotinylated rabbit anti mouse Igs
diluted 1:250 for 30 min
9. Wash in 3 changes of TBS over 5 min
10. Incubate in streptavidin-biotin-peroxidase,
diluted 1:200 for 30 min
11. Wash in 3 changes of TBS over 5 min
12. Develop peroxidase in DAB-H202 for 5-10 min
(see appendix 1) or until optimum staining is
achieved
13. Wash in tapwater
14. Stain nuclei in Mayer's haematoxylin for 1 min
15. Wash and blue in running tapwater
16. Dehydrate in alcohol, clear in xylene and mount
in synthetic resin
A positive result is shown by brown staining.
Anti CK 18 is diluted in PBS, pH 7.2 with 1% bovine
serum albumin. All other dilutions are prepared in
TBS. All incubations are at room temperature.
Negative control:
Replace primary antibody with non immune mouse serum
(step 6).
4. IMMUNOSTAINING WITH MA6 ANTIBODY174
1. Take sections to absolute alcohol
2. Block endogenous peroxidase activity in 3% H202
in methanol
3. Wash in 0.05M Tris buffered saline (TBS) (see
appendix 2)
4. Treat with trypsin (see appendix 1) at 37°C for
20 min
5. Wash in 3 changes of TBS over 3 min
6. Incubate in MA6 diluted 1:150 for 30 min
7. Wash in 3 changes of TBS over 5 min
8. Incubate in biotinylated anti mouse Igs diluted
1:250 for 30 min
9. Wash in 3 changes of TBS over 5 min
10. Incubate in streptavidin-biotin-peroxidase
diluted 1:200 for 30 rain
11. Wash in 3 changes of TBS over 5 min
12. Develop peroxidase in DAB-H202 (see appendix 1)
for 5-10 min or until optimum staining is
achieved
13. Wash in tapwater
14. Stain nuclei in Mayer's haematoxylin for 1 min
15. Wash and blue in running tapwater
16. Dehydrate in alcohol, clear in xylene and mount
in synthetic resin.
A positive result is shown by brown staining.
All dilutions are prepared in TBS and all incuba¬
tions are at room temperature.
Negative control:
Replace primary antiserum with non immune mouse
serum (step 6).
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FIGURE 9. Ra j i cells, acetone-methanol fixed and
paraffin processed. EBNA is demonstrated as brown
granularity in the nuclei. Modifled complement
anti-complement test. X1000.
FIGURE 10. A86-76. Stratified squamous epithelium.
The constantly dividing basal cells are cuboidal
with dark staining nuclei. As they mature, the
cells move towards the surface, become flattened
and their nuclei become small and pyknotic. The
epithelium is separated from the deeper lamina
propria by a basal lamina. Haematoxy1in-eosin.
X400.

FIGURE 11. A87-371. Pseudostratified ciliated
columnar epithelium. A single layer of elongated
cells, with nuclei lying at different levels,
giving the impression that there are several cell
layers. There are many mucin producing goblet
cells. The cell borders are ciliated.
Haematoxylin-eosin. X400.
FIGURE 12. A87-371. Pseudostratified ciliated
columnar epithelium. Acid mucins in the goblet
cells are stained red. Southgate's mucicarmine.
X400.

FIGURE 13. A87-371. Intermediate epithelium. A
stratified epithelium of approximately 8 layers of
cuboiaal shaped cells. There is no flattening of
the surface layers as is seen in squamous
epithelium. Haematoxylin-eosin. X400.
FIGURE 14. A87-371. Intermediate epithelium.
Higher magnification. Haematoxylin-eosin. X1000.

FIGURE 15. 86-4810 II. Pseudostratified columnar
epithelium. Immunostained with MAG antibody. Only
lymphocytes in the lamina propria are heavily
stained. X400.
FIGURE 16. 86-1162 I. Stratified squamous
epithelium at the top, and intermediate epithelium
at the bottom of the field. Immunostained with
AE1AE3. Only the deeper third of the squamous
epithelium is stained, while the full thickness of
the intermediate epithelium is stained. X 200.

FIGURE 17. A87-368. High power view of stratified
squamous epithelium. Approximately the lower third
of cells are stained. AE1AE3. X400.
FIGURE 18. 86-6445. Intermediate epithelium is
negative when immunostained with anti cytokeratin
18. X400.

FIGURE 19. A87-368. Columnar epithelium immunos-
tained with anti cytokeratin 18. The upper parti
of the cells are heavily stained, while the deepe]
parts are unstained. X1000.
FIGURE 20. 86-1788 II. The pale staining area in
the centre of the field shows squamous metaplasia,
while on either side is darkly staining inter¬
mediate epithelium. AE1AE3. X400.

FIGURE 21. 86-1162 I. Intermediate epithelium wit
patches of squamous metaplasia which are difficul
to identify in haematoxylin-eosin stained prepara
tions. X400.
FIGURE 22. 86-1162 I. Same field as figure 22 im-
munostained with AE1AE3. The pale areas shovi
squamous metaplasia. X400.

FIGURE 23. 85-4370 I. Squamous epithelium contain¬
ing koilocytes which have a perinuclear halo anc
cytoplasmic vacuolation. Also see figure 14.
X1000.
FIGURE 24. 85-3183. Squamous epithelium with
koilocytes. Immunostained with AE1AE3. The
koilocytes are unstained. X1000.

FIGURE 25. 85-2348 II. Squamous epithelium with a
proliferation of disordered cells showing hyper¬
plasia and intraepithelial neoplasia which is
stained pale. Relatively normal dark staining
epithelium in the top left hand corner. AE1AE3.
X400.
FIGURE 26. 86-5120 I. Undifferentiated nasopharyn¬
geal carcinoma. Parts of three islets of tumour
cells are clearly encapsulated by black reticulin
fibres. Gordon and Sweets' silver impregnation.
X100.

FIGURE 27. 87-443. Keratinising squamous cell
carcinoma. A clump of tumour cells surrounded by a
connective tissue stroma. The tumour cells are
showing some pink-staining keratin. Haematoxylin-
eosin. X400.
FIGURE 28. 87-443. Same case as figure 27. Keratin
is stained red with phloxine tartrazine method.
X400.

FIGURE 29. 86-5120 I. Undifferentiated nasopharyn¬
geal carcinoma. Nucleoli are prominent. Several
mitoses can be seen. Phloxine tartrazine. X400.
FIGURE 30. 85-831 I. Undifferentiated nasopharyn¬
geal carcinoma. An islet of tumour cells can be
seen in the centre of the field, amongst a dense
lymphocytic infiltrate. Haematoxyliri-eosin. X400.

FIGURE 31. 86-5020 I. Undifferentiated nasopharyn¬
geal carcinoma immunostained with M A 6. Lymphocytes
are heavily stained, squamous epithelium is
moderately stained while staining of the tumour is
pale. X400.
FIGURE 32. 87-443. Same case as figures 27 and 28.
Tumour cells stain clearly with AE1AE3. X400.

FIGURE 33. 86-4074 I. Undifferentiated nasopharyn¬
geal carcinoma. Tumour cells are clearly stained
against the connective tissue stroma and lym¬
phocyte infiltrate. AE1AE3. X400.
FIGURE 34. 86-8695 I. Undifferentiated, nasopharyn¬
geal carcinoma again is clearly demonstrated.
AE1AE3. X400.



